Medizin
Refine
Year of publication
- 2018 (472) (remove)
Document Type
- Article (439)
- Contribution to a Periodical (9)
- Doctoral Thesis (9)
- Part of Periodical (9)
- Book (3)
- Conference Proceeding (1)
- Preprint (1)
- Report (1)
Has Fulltext
- yes (472)
Is part of the Bibliography
- no (472)
Keywords
- breast cancer (15)
- Mammakarzinom (10)
- Behandlung (8)
- inflammation (7)
- CDK4/6 (6)
- Metastasen (6)
- Neuroscience (6)
- PD1/PDL1 (6)
- Studien (6)
- treatment (6)
- Blood (5)
- Research article (5)
- cancer (5)
- metastases (5)
- Biomarker (4)
- Cirrhosis (4)
- Depression (4)
- Germany (4)
- Hemorrhage (4)
- Inflammation (4)
- Prävention (4)
- Risiko (4)
- Schizophrenia (4)
- diagnosis (4)
- mutual information (4)
- pain (4)
- prevention (4)
- reactive oxygen species (4)
- risk (4)
- trials (4)
- Biomarkers (3)
- Breast cancer (3)
- Cancer (3)
- Cell staining (3)
- EEG microstates (3)
- Flow cytometry (3)
- HIV (3)
- Hepatocellular carcinoma (3)
- Liver diseases (3)
- Mental health and psychiatry (3)
- Morbidity (3)
- Neonates (3)
- Obesity (3)
- Prognosis (3)
- Stem cells (3)
- aging (3)
- autophagy (3)
- chemotherapy (3)
- entropy (3)
- glioblastoma (3)
- information theory (3)
- macrophage (3)
- metastasis (3)
- mitochondria (3)
- regeneration (3)
- sphingolipids (3)
- Alcohol consumption (2)
- Antiretroviral therapy (2)
- Atherosclerosis (2)
- Atrial fibrillation (2)
- Autism (2)
- Autism spectrum disorder (2)
- Autophagy (2)
- BRAF (2)
- Blood pressure (2)
- Brain metastasis (2)
- Brustkrebs (2)
- COPD (2)
- CTGF (2)
- Cardiac magnetic resonance (2)
- Cardiovascular diseases (2)
- Cardiovascular magnetic resonance (2)
- Cell therapy (2)
- Citation analysis (2)
- Complications (2)
- Consensus (2)
- Crystal structure (2)
- Cytoskeleton (2)
- DAA (2)
- Death rates (2)
- Deutschland (2)
- Diabetes (2)
- Diagnose (2)
- Diagnostic markers (2)
- Diagnostic medicine (2)
- Diagnostik (2)
- Emotions (2)
- Etiology (2)
- Evaluation (2)
- Everolimus (2)
- Exercise (2)
- Eyes (2)
- Face (2)
- Fistula (2)
- Früherkennung (2)
- Galaktografie (2)
- Galaktomosynthese (2)
- General practice (2)
- Genome-wide association studies (2)
- Guidelines (2)
- HCC (2)
- Hematology (2)
- Immunology (2)
- Kidney transplantation (2)
- Knees (2)
- Liver fibrosis (2)
- Lokalrezidiv (2)
- Long non-coding RNAs (2)
- MRI (2)
- MRT (2)
- Mamma (2)
- Markovianity (2)
- Medical education (2)
- MicroRNAs (2)
- Mixed methods (2)
- Morphometry (2)
- Mortality (2)
- Multimorbidity (2)
- Multiple chronic conditions (2)
- Musculoskeletal system (2)
- Nachsorge (2)
- Nerve fibers (2)
- Next-generation sequencing (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Operation/Chirurgie (2)
- PCR (2)
- PD1/ PDL1 (2)
- Palliative care [MeSH] (2)
- Patients (2)
- Percutaneous coronary intervention (2)
- Periodontitis (2)
- Polypharmacy (2)
- Primary care (2)
- Prognosefaktoren (2)
- Prostate cancer (2)
- Prädiktivfaktoren (2)
- Pulmonary hypertension (2)
- Reaction time (2)
- Richtlinie (2)
- Scientists (2)
- Sepsis (2)
- Stroke (2)
- Surgical and invasive medical procedures (2)
- Surgical oncology (2)
- Survival (2)
- Sweden (2)
- Teeth (2)
- Tomosynthese (2)
- Trauma (2)
- Ultraschall (2)
- Validation (2)
- Viral load (2)
- Vitamin D (2)
- Vitamin D deficiency (2)
- acute kidney injury (2)
- angiogenesis (2)
- antioxidants (2)
- ataxia telangiectasia (2)
- atherosclerosis (2)
- attention (2)
- bioinformatics (2)
- breast (2)
- cardiac surgery (2)
- catheter ablation (2)
- ceramides (2)
- child (2)
- chronic kidney disease (2)
- connectivity (2)
- cytokines (2)
- data science (2)
- development (2)
- endothelial cells (2)
- epilepsy (2)
- follow‑up (2)
- forensic entomology (2)
- galactography (2)
- galactomosynthesis (2)
- guideline (2)
- hedgehog signaling (2)
- hepatitis C virus (2)
- human (2)
- hyperglycemia (2)
- hypoxia (2)
- imaging (2)
- immunotherapy (2)
- innate immunity (2)
- interleukin-4 (2)
- liver injury (2)
- local recurrence (2)
- lyme disease (2)
- matrix (2)
- medical students (2)
- mesenchymal stromal/stem cells (2)
- metabolism (2)
- miRNA (2)
- microRNA (2)
- minimalinvasive Biopsie (2)
- minimally invasive biopsies (2)
- neoadjuvant chemotherapy (2)
- neoadjuvante Chemotherapie (2)
- next generation sequencing (NGS) (2)
- obesity (2)
- paclitaxel (2)
- predictive factors (2)
- pregnancy (2)
- primary immunodeficiency (2)
- prognostic factors (2)
- psoriasis (2)
- radiation (2)
- rapamycin (2)
- reproducibility (2)
- resistance (2)
- safety (2)
- schizophrenia (2)
- screening (2)
- seizure (2)
- sphingosine 1-phosphate (2)
- spreadsheet (2)
- stationarity (2)
- studies (2)
- surgery (2)
- tobacco prevention (2)
- tomosynthesis (2)
- treatment/therapy (2)
- ultrasound (2)
- vector (2)
- vemurafenib (2)
- workflow (2)
- (surface) partial differential equations (1)
- 1,2-dichloroethane (1)
- 1,25-Dihydroxyvitamin D (1)
- 16p11.2 (1)
- 2-deoxyglucose (2-DG) (1)
- 3D spatio-temporal resolved mathematical models (1)
- 4-FA (1)
- A375 human melanoma cells (1)
- A549 (1)
- ACE-inhibitor (1)
- ACURATE neo (1)
- ADHD (1)
- AIDS (1)
- AKI (1)
- ALK gene (1)
- ALK-rearranged NSCLC (1)
- ARA (1)
- ARFI (1)
- ASO (1)
- ATP-citrate lyase (1)
- Abatacept (1)
- Acoustics (1)
- Activities of daily living (1)
- Acute bronchitis (1)
- Acute cough (1)
- Acute lymphocytic leukaemia (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Adipose-derived mesenchymal stem cells (1)
- Adults (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Age (1)
- Age groups (1)
- Aggressive periodontitis (1)
- Akaike information criterion (AIC) (1)
- Aliphatic halogenated hydrocarbons (1)
- Alleles (1)
- Allergic asthma (1)
- Allgemeinmedizin (1)
- Alveolar ridge augmentation (1)
- Ambroxol (1)
- Anatomie (1)
- Anatomie und Histologie (1)
- Andexanet alpha (1)
- Angioedema (1)
- Angiogenesis (1)
- Angioplasty (1)
- Animal wings (1)
- Anomalie <Medizin> (1)
- Antibiotics (1)
- Antibodies (1)
- Antibody-mediated rejection (1)
- Anticoagulant therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Antithrombotic therapy (1)
- Antiviral agents (1)
- Antiviral therapy (1)
- Apixaban (1)
- Apoptosis (1)
- Aquaporins (1)
- Arms (1)
- Ascites (1)
- Aspergillus (1)
- Asphyxia (1)
- Atrial appendage occlusion (1)
- Attention (1)
- Attention-deficit / hyperactivity disorder (1)
- Attitude (1)
- Aurora A (1)
- Austria (1)
- Auto transfusion (1)
- Autoimmunity (1)
- Autopsy (1)
- Axons (1)
- Azathioprine (1)
- B cell subpopulations (1)
- B cells (1)
- B-cell immunology (1)
- B-cell lymphoma (1)
- BATF3 (1)
- BCG-Therapie (1)
- BCR signaling (1)
- BIAM-switch (1)
- BMC (1)
- BPD (1)
- BRCA1 (1)
- BRCA2 (1)
- BTK (1)
- Babesia divergens (1)
- Babesia microti (1)
- Bacterial meningitis (1)
- Bacterial pathogens (1)
- Bayesian inference (1)
- Behavioral analysis (1)
- Benefit (1)
- Best practice (1)
- Bibliometrics (1)
- Bidirectional genes (1)
- Big Data (1)
- Big data (1)
- Big five (1)
- Biofluids (1)
- Bioinformatics (1)
- Biological (1)
- Biological invasion (1)
- Biomechanical analysis (1)
- Biophysical models (1)
- Biopsy (1)
- Biosynthetic mesh (1)
- Bipolar disorder (1)
- Birth weight (1)
- Blasenkarzinom (1)
- Blended learning curriculum · (1)
- Blended-Learning-Curriculum (1)
- Blood cells (1)
- Blood groups (1)
- Blood-brain barrier (1)
- Bloodstream infections (1)
- Blurred vision (1)
- Blutgefäß (1)
- Bone defect (1)
- Bone marrow cells (1)
- Bone marrow fibrosis (1)
- Bone marrow mononuclear cells (1)
- Bone marrow-derived mesenchymal stem cells (1)
- Bone tissue engineering (1)
- Borrelia (1)
- Borrelia burgdorferi (1)
- Borrelia miyamotoi (1)
- Bradykinin (1)
- Brain anatomy (1)
- Brain damage (1)
- Brain ischemia (1)
- Breast tumors (1)
- Bright light therapy (1)
- Bronchial inflammation (1)
- Bronchitis severity scale (1)
- Bronchopulmonary dysplasia (1)
- Burden of disease (1)
- Bypass liner (1)
- C-reactive protein (1)
- C. elegans (1)
- C1 inhibitor (1)
- C1-inhibitor (1)
- C5 acylcarnitine (1)
- CCL2 (1)
- CCN2 (1)
- CD3/19 depletion (1)
- CD34 selection (1)
- CD36 (1)
- CD74 (1)
- CDK4/6 inhibitor (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CNS (1)
- CO2-induced forced ventilation (1)
- COI (1)
- COII (1)
- COMT (1)
- COPD course and therapy (1)
- CRE-luciferase (1)
- CRISPR/Cas9 (1)
- CRM1 (1)
- CTX (1)
- Ca2+ imaging (1)
- Caffeine (1)
- Calcium signalling (1)
- Calnexin (1)
- Cancer detection and diagnosis (1)
- Cancer epidemiology (1)
- Cancer treatment (1)
- Carbon tetrachloride (1)
- Cardiac Fibrosis (1)
- Cardiac surgery (1)
- Cardiac surgery patients (1)
- Cardiomyopathy (1)
- Cardiovascular biology (1)
- Cardiovascular disease (1)
- Cardiovascular genetics (1)
- Cell binding (1)
- Cell cultures (1)
- Cell distribution (1)
- Cell membranes (1)
- Cell salvage (1)
- Cell signalling (1)
- Cementation (1)
- Ceramic (1)
- Cerclage (1)
- Cerebral ischemia (1)
- Cerebrospinal fluid (1)
- Certification (1)
- Cesarean section (1)
- Chaperone (1)
- Chemical biology (1)
- Chemical ecology (1)
- Chemobrain (1)
- Chemoembolization (1)
- Chest pain unit (1)
- Chikungunya virus (1)
- Child (1)
- Children (1)
- Chloroform (1)
- Chondrocytes (1)
- Chromatin accessibility (1)
- Chromatin and Epigenetics (1)
- Chronic heart failure (1)
- Chronic periodontiti (1)
- Chronification (1)
- Circadian rhythms and sleep (1)
- Cleanliness level (1)
- Clinical frailty scale (1)
- Clinical genetics (1)
- Clinical outcome (1)
- Clinical psychometry (1)
- Clinical study (1)
- Clinical trials (1)
- Closure (1)
- Co-culture (1)
- Co-morbidity (1)
- Cocaine (1)
- Cognition (1)
- Cognitive neuroscience (1)
- Colon cancer (1)
- Colon capsule endoscopy (1)
- Comparative effectiveness research (1)
- Complement system (1)
- Complementation rate (1)
- Complete heart block (1)
- Complex I (1)
- Complex II (1)
- Complex hernia (1)
- Complex networks (1)
- Complication management (1)
- Connective tissue (1)
- Consortia (1)
- Conventional synthetic disease-modifying antirheumatic drug (1)
- Coronary artery disease (1)
- Coronary intervention (1)
- Credentialing (1)
- Critical bleeding (1)
- Crohn’s disease (1)
- CspZ (1)
- Curriculum (1)
- Cystic fibrosis (1)
- Cytokines (1)
- Cytology (1)
- DAMP (1)
- DLBCL (1)
- DMARDs (biologic) (1)
- DMARDs (synthetic) (1)
- DNA methylation (1)
- DNA mismatch repair (1)
- DNase1-seq (1)
- DOK1 (1)
- DSM (1)
- DTI (1)
- Dabigatran (1)
- Data acquisition (1)
- Data processing (1)
- Data science (1)
- Data visualization (1)
- Decision making (1)
- Deformation (1)
- Dengue (1)
- Dengue fever (1)
- Dengue virus (1)
- Density equalizing mapping (1)
- Dental implants (1)
- Dental phobia (1)
- Dental training (1)
- Dentition (1)
- Dermatomyositis (1)
- Developmental biology (1)
- Diabetes mellitus (1)
- Diagnosis (1)
- Dichloromethane (1)
- Differentiation (1)
- Digital ethics (1)
- Digital rectal examination (1)
- Digital transformation (1)
- Digitale Ethik (1)
- Digitale Transformation (1)
- Dimer (1)
- Dimers (Chemical physics) (1)
- Direct current electrical stimulation (1)
- Disc herniation (1)
- Dissociative seizures (1)
- Distance to water (1)
- Donor Selection (1)
- Dopamine (1)
- Drug discovery (1)
- Drug interactions (1)
- Drug therapy (1)
- Dual therapy (1)
- E/I-Balance (1)
- EGFL7 (1)
- EMT (1)
- ENCODE-DREAM in vivo Transcription Factor binding site prediction challenge (1)
- ERMS (1)
- Early diagnosis (1)
- Early recurrence (1)
- Edoxaban (1)
- Elderly (1)
- Elective caesarean section (1)
- Elevation (1)
- Ellipsoids (1)
- Emotional recognition (1)
- Endocrine cancer (1)
- Endoscopy (1)
- England (1)
- Ensemble learning (1)
- Enterostomy (1)
- Enterostomy closure (1)
- Enterostomy formation (1)
- Environmental chemistry (1)
- Enzyme kinetics (1)
- Enzyme mechanisms (1)
- Epidemiology (1)
- Epidermal growth factor receptor (1)
- Epidural block (1)
- Epigenetics (1)
- Epileptic seizures (1)
- Epithelial cells (1)
- Epstein-Barr virus (1)
- Epstein–Barr virus (1)
- Equipment (1)
- Ergonomics (1)
- Estradiol (1)
- Europe (1)
- European registry for idiopathic pulmonary fibrosis (eurIPFreg) (1)
- Examination questions (1)
- Exosomes (1)
- Experimental models of disease (1)
- Extinction (1)
- Extracellular matrix (1)
- Extracellular matrix proteins (1)
- Extracorporeal purification (1)
- Eye movements (1)
- FAM134B (1)
- FGFR (1)
- FOXO3a (1)
- FTY720 (1)
- FX06 (1)
- Factor analysis (1)
- Fallbeispiele (1)
- Fatiguesyndrom (1)
- Fear conditioning (1)
- FibroScan (1)
- Fibroblasts (1)
- Fibrosis (1)
- Finite Element Method (1)
- Finite Volumes (1)
- Flaps (1)
- Forensics (1)
- Formation dance (1)
- Frailty (1)
- Frühgeburt (1)
- Functional clustering (1)
- G2A (1)
- GABAergic interneurons (1)
- GLI inhibitors (1)
- GPCR (1)
- GSK3α (1)
- GSK3β (1)
- Games (1)
- Gamma-Band Activity (1)
- Gap junctions (1)
- Gastric cancer (1)
- Gastrointestinal cancer (1)
- Gastrointestinal tract (1)
- Gebärmutterhalskrebs (1)
- Gender gap (1)
- Gene Regulation (1)
- Gene expression (1)
- Gene fusion (1)
- Gene microarray analysis (1)
- Gene therapy (1)
- General dental practice (1)
- Generation time (1)
- Geographically weighted regression (GWR) (1)
- German people (1)
- Gestational age (1)
- Glaucoma (1)
- Glioblastoma (1)
- Glycosphingolipids (1)
- Grafts (1)
- Gram negative bacteria (1)
- Greater tuberosity fractures (1)
- Growth factors (1)
- HACA (1)
- HBV reactivation (1)
- HCV treatment (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HH (1)
- HIV serodiagnosis (1)
- HIV-1 (1)
- HLA class II (1)
- HLA peptidome (1)
- HMGB1 (1)
- HPV (1)
- HRas (1)
- Haematoma expansion (1)
- Haemostatics (1)
- Hashimoto’s thyroiditis (1)
- Hausarztmangel (1)
- Head injury (1)
- Health care resource utilization (1)
- Health economics (1)
- Health information (1)
- Health risk analysis (1)
- Health-seeking behaviour (1)
- Heart transplantation (1)
- Hedgehog pathway (1)
- Helpline (1)
- Hematocrit value (1)
- Hematopoietic stem cell transplantation (1)
- Hemodynamics (1)
- HepG2 (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatitis C virus (1)
- Hepatitis C, Chronic (1)
- Herbalife (1)
- Hereditary breast and ovarian cancer (1)
- HhAntag (1)
- High-intensity interval endurance training (1)
- Hindu Kush Himalayas (1)
- Hip (1)
- Histology (1)
- Histone post-translational modifications (1)
- Homeostasis (1)
- Horner's syndrome (1)
- Horses (1)
- HuR (1)
- Human behaviour (1)
- Human prostate (1)
- Hydroxychloroquine (1)
- Hydroxycut (1)
- Hydroxyurea (1)
- Hypoxia inducible factor (1)
- Hysterektomie-Prävalenz (1)
- IFN (1)
- IL-18BP (1)
- IL-1β (1)
- IL-6 (1)
- IRES translation (1)
- ITGA7 (1)
- IVA interference tandem mass spectrometry (1)
- Iceland (1)
- Idarucizumab (1)
- Idiopathic pulmonary fibrosis (IPF) (1)
- Imaging (1)
- Imaging in LGG (1)
- Immune suppression (1)
- Immunosenescence (1)
- Immunotherapy (1)
- Implementation (1)
- Incisional hernia (1)
- Incomplete colonoscopy (1)
- Indirect-binding (1)
- Induced sputum (1)
- Infectious disease epidemiology (1)
- Inflammatory diseases (1)
- Injuries (1)
- Injury (1)
- Insulin (1)
- Intensive care outcome (1)
- Intensive care units (1)
- Interferon-frei (1)
- Interleukin-6 (1)
- Interspecific competition (1)
- Interstitial lung diseases (ILD) (1)
- Intervertebral disc degeneration (1)
- Intra-abdominal infection (1)
- Intracellular pathogens (1)
- Intracerebral haemorrhage (1)
- Intracranial haemorrhage (1)
- Intracranial hemorrhage (1)
- Intragastric balloon (1)
- Inzidenzkorrektur (1)
- Irregular vaccination (1)
- Italy (1)
- Ivor Lewis esophagectomy (1)
- JNK3 (1)
- Jaw (1)
- Jumping (1)
- KAP (1)
- KDIGO (1)
- Kaisidis plate (1)
- Kidney Transplantation (1)
- Kidney transplant recipients (1)
- Knowledge (1)
- Krebsforschung (1)
- Kupffer cells (1)
- Kynurenine (1)
- LCH (1)
- Labor and delivery (1)
- Lactic acidosis (1)
- Landarztprogramm (1)
- Langerhans cell histiocytosis (1)
- Language (1)
- Laparostomy (1)
- Laterality (1)
- Lebensqualität (1)
- Leberzirrhose (1)
- Lectin affinity plasmapheresis (1)
- Leflunomide (1)
- Legs (1)
- Lernerfolgsmessung (1)
- Lesions (1)
- Leukocyte elastase (1)
- Light sheet fluorescence microscopy (1)
- Linear regression analysis (1)
- Lipidol (1)
- Lipopolysaccharide-binding protein (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Livestock (1)
- LncRNA (1)
- Local climate (1)
- Local control (1)
- Locomotor circuit (1)
- Low volume prep (1)
- Low-grade glioma (1)
- Luciferase (1)
- Lumbar spine (1)
- Lung adenocarcinoma (1)
- Lymphom (1)
- Lymphozyt (1)
- Lysosome (1)
- MDR1 (1)
- MEIS2 (1)
- MET (1)
- MOLLI (1)
- MR spectroscopy (1)
- MR-proADM (1)
- MRP4 (1)
- Machine learning (1)
- Macrophages (1)
- Malaria (1)
- Mammalian target of rapamycin (1)
- Marburg virus (1)
- Maternal morbidity (1)
- Maxillary sinus (1)
- Medical communication (1)
- Medical ethics (1)
- Medical hypoxia (1)
- Medical imaging (1)
- Medical risk factors (1)
- Medical traineeship (1)
- Medication Appropriateness Index (1)
- Medication changes (1)
- Medizinische Abbildung (1)
- Medizinische Ausbildung (1)
- Medizinstudierende (1)
- Medizinstudium (1)
- Membrane proteins (1)
- Membrane staining (1)
- Mentor (1)
- Mesangial cells (1)
- Mesh (1)
- Mesh repair (1)
- Messenger RNA (1)
- Metabolic syndrome (1)
- Methotrexate (1)
- Micro RNAs (1)
- Micro-CT (1)
- Microalgae (1)
- Microbial mutation (1)
- Microbiome (1)
- Microsatellite instability (1)
- Middle East respiratory syndrome coronavirus (1)
- Midline laparotomy (1)
- Minimal core of imaging (1)
- Minimal invasive (1)
- Mitochondria (1)
- Mitochondrial ROS (1)
- Mitochondrial disorder (1)
- Mitochondrial proteins (1)
- Mitochondrial respiration (1)
- MitraClip (1)
- Model Organism (1)
- Molecular genetics (1)
- Molecular medicine (1)
- Monocytes and macrophages (1)
- Monolithic crown (1)
- Monte Carlo method (1)
- Morphogenesis (1)
- Mortalitätskorrektur (1)
- Motor skills (1)
- Mountain (1)
- Mouse (1)
- Mouse model (1)
- Mouse models (1)
- Moviprep (1)
- Multi-modal feedback (1)
- Multidisciplinary management (1)
- Multidrug resistance (1)
- Multiple sclerosis (1)
- Multivariate analysis (1)
- Muscle tissue (1)
- Musician-specific seating position (1)
- Myalgia (1)
- Myelofibrosis (1)
- Myocardial infarction (1)
- Myocardial revascularization (1)
- N-Acetylaspartate (1)
- N-acetylcysteine (1)
- N-methyl-D-aspartate receptor (1)
- NAFLD (1)
- NASH (1)
- NDNF interneurons (1)
- NDUFA6 (1)
- NK cells (1)
- NKG2A blocking (1)
- NKG2D (1)
- NK cells (1)
- NOD2 (1)
- NSTEMI (1)
- Nanoparticles (1)
- Natriuretic peptide (1)
- Necrosis (1)
- Necrotizing enterocolitis (1)
- Needs assessment [MeSH] (1)
- Negative staining (1)
- Neoadjuvant therapy (1)
- Neonatal (1)
- Neonatal intensive care unit (1)
- Neonatal morbidity (1)
- Nephrons (1)
- Nerve regeneration (1)
- Nerves (1)
- Neural circuits (1)
- Neurobiology of disease and regeneration (1)
- Neurodevelopment (1)
- Neuroendocrine cancer (1)
- Neuroimaging (1)
- Neutropenia (1)
- Next generation sequencing (1)
- Nfe2l2 (1)
- Niche differentiation (1)
- Nimotuzumab (1)
- Nitric oxide (1)
- Non-interventional study (1)
- Non-responder (1)
- Non-small-cell lung cancer (1)
- Non-trauma (1)
- Noncoding RNA (1)
- Normal distribution (1)
- Nox1 (1)
- Nox4 (1)
- NoxO1 (1)
- Nucleus pulposus cells (1)
- Nutrition (1)
- Nymphs (1)
- OCT (1)
- Observational studies (1)
- Obstetrics and gynecology (1)
- Ocular findings (1)
- Oesophageal cancer (1)
- Okinawa (1)
- Okinawa diet (1)
- Older adults (1)
- Oncologic surgery (1)
- Open abdomen (1)
- Optic nerve atrophy (1)
- Optogenetics (1)
- Oral and maxillofacial trauma (1)
- Oral anticoagulation (1)
- Oral surgery (1)
- Ordinary least squares (OLS) (1)
- Organ dysfunction (1)
- Organ dysfunctions (1)
- Organ support (1)
- Organs at Risk (1)
- Oroantral (1)
- Osimertinib (1)
- Osteogenic differentiation (1)
- Outcome assessment (1)
- Outcome assessment [MeSH] (1)
- OxyELITE Pro (1)
- P-gp (1)
- P1NP (1)
- P2X7 receptor (1)
- PAH (1)
- PAI-1 (1)
- PBX1 (1)
- PC12 cells (1)
- PCV (1)
- PD-L1 (1)
- PEGylated PLGA (PLGA-PEG) (1)
- PFL (1)
- PI3K (1)
- PKA (1)
- PTCH (1)
- PTDM (1)
- PTK2B (1)
- Pacemaker (1)
- Pain (1)
- Pancreatitis (1)
- Parkin (1)
- Parkinson disease (1)
- Pathological complete response (1)
- Pathology (1)
- Patient Blood Management (1)
- Patient Outcome Assessment (1)
- Patient satisfaction (1)
- Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (1)
- Pediatrics [MeSH] (1)
- Peer Teaching (1)
- Peer teaching (1)
- Periodontal diseases (1)
- Peritonitis (1)
- Personality (1)
- Personalized medicine (1)
- Pessar (1)
- Pharmacy setting (1)
- Pharyngeal reflex (1)
- Phospho-soda (1)
- Phospholipids (1)
- Phosphorylation (1)
- Phylogenetic analysis (1)
- Physical environment (1)
- Physicians (1)
- Physiology (1)
- PillCamColon2 (1)
- Polyps (1)
- Portal hypertension (1)
- Position paper (1)
- Post-transplant (1)
- Postoperative infections (1)
- Posttranslational modification (1)
- Postural control (1)
- Poverty (1)
- Practice (1)
- Preclinical (1)
- Pregnancy (1)
- Preterm birth (1)
- Primary health care (1)
- Progesteron (1)
- Progesterone (1)
- Prognostic markers (1)
- Programming languages (1)
- Progranulin (1)
- Proliferation (1)
- Prostate Cancer (1)
- Prostate cancer cell lines (1)
- Prosthetic rehabilitation (1)
- Protein domains (1)
- Protein translation (1)
- Proteins (1)
- Prothrombin complex concentrate (1)
- Prüfungsfragen (1)
- Psychiatric disorders (1)
- Psychology (1)
- Public and occupational health (1)
- Pulmonary artery pressure (1)
- Pulmonary embolism (1)
- Pyruvate (1)
- Qualitative research [MeSH] (1)
- Quality of health care [MeSH] (1)
- Quality of life (1)
- Quantitative MRI (1)
- Quantitative trait loci (1)
- Questionnaires (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- RNA therapy (1)
- RNA viruses (1)
- ROS (1)
- Rab7 (1)
- Radical nephrectomy (1)
- Rainfall (1)
- Randomized (1)
- RapL (1)
- Rapamycin (1)
- Rare diseases (1)
- Re-exploration (1)
- Rearing temperature (1)
- Red blood cell transfusion (1)
- Redox modification (1)
- Regeneration (1)
- Regression analysis (1)
- Regulatory networks (1)
- Reintervention (1)
- Remote monitoring (1)
- Renal cancer (1)
- Renal system (1)
- Research Article (1)
- Research architecture (1)
- Resource competition (1)
- Respiratory tract diseases (1)
- Response criteria (1)
- Resuscitation (1)
- Retinal degeneration (1)
- Rheumatoid arthritis (1)
- Rivaroxaban (1)
- Rural area (1)
- Ruxolitinib (1)
- S1P (1)
- SAVI (1)
- SCMR (1)
- SDH (1)
- SKAP1 (1)
- SMAD signaling (1)
- SOFA (1)
- STING (1)
- Safety equipment (1)
- Safety learning (1)
- Sarcoidosis (1)
- Scientific publishing (1)
- Secretion (1)
- Senescence (1)
- Sensitivity (1)
- Sensory Neuroscience (1)
- Sensory processing (1)
- Septic shock (1)
- Sequence alignment (1)
- Serum (1)
- Severe blood loss (1)
- Severity of illness index (1)
- Sex differences (1)
- Shannon index (1)
- Sholl analysis (1)
- Simulated patients (1)
- Single-cell RNA-seq (1)
- Smac mimetic (1)
- Small molecules (1)
- Small-cell lung cancer (1)
- Smart nebulizer (1)
- Smoking habits (1)
- Social communication (1)
- Social research (1)
- Social sciences (1)
- Solidworks 2015 (1)
- Sphingolipids (1)
- Spine Register (1)
- Spirochetes (1)
- Sports (1)
- Sports and exercise medicine (1)
- Spot sign (1)
- Standards of care (1)
- Starvation (1)
- Statistical data (1)
- Statistical methods (1)
- Status epilepticus (1)
- Stenotrophomonas maltophilia (1)
- Stereotactic radiosurgery (1)
- Stoma (1)
- Streptococcus pneumoniae (1)
- Stringed bow player (1)
- Structural MRI (1)
- Structural genomics (1)
- Study protocol (1)
- Suicide (1)
- Sulfasalazine (1)
- Sumatra (1)
- Supraspinatus tendon (1)
- Surgical ICU (1)
- Surgical site occurrence (1)
- Survival analysis (1)
- Survival data (1)
- Sweat osmolality (1)
- Sweat secretion rate (1)
- Syncope (1)
- Synthetic (1)
- T cell (1)
- T cells (1)
- T helper 17 cells (1)
- T-DM1 (1)
- T-cell targeting (1)
- T-cells (1)
- T1 mapping (1)
- TALE-homdomain protein (1)
- TAVR (1)
- TBSS (1)
- TC stenosis (1)
- TF-complexes (1)
- TMS-EEG (1)
- TNF inhibitors (1)
- TNF-α (1)
- TOR inhibitor (1)
- TP53 mutation status (1)
- Targeted therapy (1)
- Taxonomy (1)
- Technique (1)
- Telemedicine (1)
- Temporal lobe epilepsy (1)
- Term birth (1)
- Testosterone (1)
- Tet-inducible system (1)
- Thailand (1)
- Thermoregulation (1)
- Three-dimensional back scan (1)
- Thrombosis (1)
- Thyroid (1)
- Tick-Borne diseases (1)
- Tick-borne encephalitis (1)
- Timing (1)
- Tinnitus (1)
- Tomography (1)
- Tooth transplantation (1)
- Torque (1)
- Toxicity (1)
- Training (1)
- Tranexamic acid (1)
- Transcription (1)
- Transcription Factors (1)
- Transcription factors (1)
- Transferases (1)
- Transfusion (1)
- Transgenic SK-2 mice (1)
- Trauma surgery (1)
- Traumatic brain injury (1)
- Traumatic injury (1)
- Treatment (1)
- Trichuris suis ova (1)
- Triple negative (1)
- Triple therapy (1)
- Triple-negative breast cancer (1)
- Troponin (1)
- Tubers (1)
- Tumor infiltrating lymphocytes (1)
- Tumour biomarkers (1)
- Type 2 diabetes (1)
- UDP-glucose ceramide glycosyltransferase (1)
- UGCG (1)
- ULBP4 (1)
- UWB diagnostics (1)
- Ubiquitin (1)
- Ubiquitination (1)
- Ultra microscopy (1)
- Ultrasonic nebulizer (1)
- Ultrasound imaging (1)
- Upper body posture (1)
- Usutu virus (1)
- V4 (1)
- VEGF (1)
- VIP1 (1)
- Vaccination breakthrough (1)
- Vaccine (1)
- Vascular emergencies (1)
- Vector mosquito (1)
- Viral core (1)
- Viral replication (1)
- Vision (1)
- Visual acuity (1)
- Vitamin (1)
- Volumetric analysis (1)
- Vorklinik (1)
- Warburg effect (1)
- Water chemistry (1)
- Weight loss (1)
- West Nile fever (1)
- West Nile neuroinvasive disease (1)
- West Nile virus (1)
- Work shadowing (1)
- Working memory (1)
- X-ray crystallography (1)
- XL probe (1)
- Yarrowia lipolytica (1)
- Zervixverkürzung (1)
- Zika (1)
- Zika vaccine (1)
- Zika virus (1)
- Zirconia (1)
- Zoopotentation (1)
- Zooprophylaxis (1)
- abemaciclib (1)
- abnormal tumor vasculature (1)
- accident (1)
- acetaminophen (1)
- acetyl-CoA (1)
- activation receptors (1)
- active/deactive transition (1)
- actography (1)
- acute cholecystitis (1)
- acute coronary syndrome (1)
- acute exacerbations of COPD (1)
- acute inflammation (1)
- acute myeloid leukemia (1)
- adaptation (1)
- adenosine receptors (1)
- adherence (1)
- adhesion (1)
- adipose-derived mesenchymal stem cells (1)
- adoptive cell therapy (1)
- adoptive immunotherapy (1)
- advanced breast cancer (1)
- adverse reaction (1)
- aerosol (1)
- aggression (1)
- airway remodeling (1)
- aliphatic halogenated hydrocarbons (1)
- alirocumab (1)
- allergen immunotherapy (1)
- allergic rhinitis (1)
- allogeneic stem cell transplantation (1)
- alpinia zerumbet (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- anastomotic leakage (1)
- anatomy (1)
- anatomy and histology (1)
- anti-GD2 immunotherapy (1)
- anti-inflammatory (1)
- antibiotic (1)
- antibiotic therapy (1)
- antibodies (1)
- anticonvulsants (1)
- antihormone therapy (1)
- antimicrobial activity (1)
- antioxidant (1)
- antioxidant activity (1)
- antisense oligonucleotides (1)
- aortic stenosis (1)
- apoptosis (1)
- apps (1)
- aptamer (1)
- aquaporin 1 (1)
- arachidonate 15-lipoxygenase (1)
- arachidonic acid (1)
- ascites (1)
- asthma (1)
- atrial fibrillation (1)
- atrial septostomy (1)
- atrophy (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- avelumab (1)
- back scan (1)
- bacterium (1)
- balanced state (1)
- basal cell carcinoma (1)
- basic leucine zipper transcription factor ATF-like (1)
- beta blockade (1)
- betamethasone dipropionate (1)
- bevacizumab (1)
- bibliometric analysis (1)
- bibliometry (1)
- bio imaging (1)
- bioactive phytochemicals (1)
- bioluminescence (1)
- biomarker (1)
- biopsy (1)
- bipolar disorders (1)
- birch pollen allergoid (1)
- blood (1)
- blood donor (1)
- blow flies (1)
- blow fly (1)
- body posture (1)
- borrelia (1)
- brachytherapy (1)
- bronchodilator (1)
- buccal mucosa (1)
- cAMP (1)
- cFLIP (1)
- calcification score (1)
- calcipotriol (1)
- calcium-independent phospholipase A2β (1)
- cancer stem cells (1)
- carbon tetrachloride (1)
- cardiovascular diseases (1)
- cardiovascular precision medicine (1)
- caspase-2 (1)
- ceRNA (1)
- celery (1)
- cell biology (1)
- cell cycle (1)
- cell migration (1)
- cellular signalling (1)
- centenarians (1)
- cerclage (1)
- cerebrospinal fluid (1)
- cervical cancer (1)
- cervical shortening (1)
- cervical spine (1)
- cervico-thoracic junction (1)
- ch14.18/CHO (1)
- chamomile (1)
- checkpoint inhibition (1)
- chemokine (1)
- chemotaxis (1)
- chemotherapeutic drug resistance (1)
- child abuse and neglect (1)
- child maltreatment (1)
- children (1)
- cholangiocarcinoma (1)
- cholesterol (1)
- chromosomal integration (1)
- cilia (1)
- circadian rhythms (1)
- circadian variation (1)
- cisplatin resistance (1)
- clinical management (1)
- clinical practice (1)
- clinical trial (1)
- cognition (1)
- cognitive states (1)
- cohort study (1)
- colitis (1)
- collagen (1)
- collagen-based biomaterial (1)
- collective dynamics (1)
- colon (1)
- colon carcinoma cells (1)
- column chromatography (1)
- combination (1)
- combination therapy (1)
- combined immunodeficiency (1)
- complement dependent cytotoxicity (1)
- complementary information (1)
- complex I (1)
- complexome profiling (1)
- complications (1)
- computational virology (1)
- computer-assisted drug therapy (1)
- congenic mice (1)
- contact lens solution (1)
- continuous glucose monitoring (1)
- controlled nuclear import (1)
- coronary (1)
- coronary disease (1)
- correction of incidence rate (1)
- correction of mortality rate (1)
- corrosion (1)
- criticality (1)
- cryoballoon (1)
- cumulative dose (1)
- curriculum (1)
- cytarabine dose (1)
- cytochrome P450 2E1 (1)
- cytokine release syndrome (1)
- cytokine-induced killer cells (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- damage associated molecular pattern (1)
- decision aids (1)
- delayed cholecystectomy (1)
- delta-9-tetrahydrocannabinol (1)
- dendritic cells (1)
- dendritic inhibition (1)
- dental abutment (1)
- dental implants (1)
- dermatology (1)
- dexamethasone (1)
- diabetes (1)
- diabetic macular edema (1)
- diagnostics (1)
- dietary supplements (1)
- differentiated thyroid carcinoma (1)
- differentiation (1)
- diffuse low-grade glioma (1)
- digital age determination (1)
- dihydroceramides (1)
- diplopia (1)
- direct-acting antivirals (1)
- disease progression (1)
- disintegration (1)
- dose response curve (1)
- doxorubicin (1)
- doxycycline (1)
- drug interaction (1)
- drug release (1)
- drug-coated balloon (1)
- drug-eluting balloon (1)
- dynamic stimuli (1)
- eNPP2 (1)
- early cholecystectomy (1)
- educational cases (1)
- educational measurement (1)
- efficacy (1)
- elderly (1)
- embodiment (1)
- emulsion diffusion (1)
- encoding (1)
- endogenous clock (1)
- endoplasmic reticulum (1)
- endothelial activation (1)
- endothelial barrier (1)
- endothelial cell (1)
- endothelial nitric-oxide synthase (1)
- epidemics (1)
- epidemiology (1)
- epileptic encephalopathies (1)
- event-based (1)
- excitability (1)
- exercise (1)
- exosomes (1)
- exponential model (1)
- extracting solvents (1)
- fMRI (1)
- face (1)
- facial EMG (1)
- facial emotion recognition (1)
- facial expressions of emotion (1)
- facial muscle activity (1)
- factor H (1)
- falls (1)
- false memory (1)
- fear learning (1)
- female subjects (1)
- femoropopliteal segment (1)
- fibrinolysis (1)
- fibrosis (1)
- flow cytometry (1)
- fluocinolone acetonide (1)
- focal adhesion (1)
- forensics (1)
- functional connectivity (1)
- functional genomics (1)
- functional magnetic resonance imaging (fMRI) (1)
- fungus (1)
- galactomannan (1)
- gallstone disease (1)
- gastric cancer (1)
- gastro-oesophageal junction cancer (1)
- gene delivery (1)
- gene therapy (1)
- gene vectors (1)
- general anaesthesia (1)
- general practice (1)
- genetic markers (1)
- geriatric medicine (1)
- germinal center (1)
- glioma (1)
- glioma-associated oncogene homolog (1)
- gliomas (1)
- global mapping (1)
- glucocorticoid (1)
- glucose metabolism (1)
- glycolysis (1)
- graft perfusion (1)
- graft rejection (1)
- graft-versus-host disease (1)
- graft-versus-tumor effect (1)
- granulocytemacrophage colony-stimulating factor (1)
- granulomas (1)
- granulomatous inflammation (1)
- green tea extract (1)
- hanging donors (1)
- head and neck squamous cell carcinoma (1)
- head-and-neck cancer (1)
- headache (1)
- health (1)
- health care personnel (1)
- health information exchange (1)
- health services accessibility (1)
- health-related quality of life (1)
- heart failure (1)
- hedgehog signaling pathway (1)
- helminths (1)
- hematopoietic stem cells (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- hepatitis E virus (1)
- hepatocyte transplantation (1)
- hereditary angioedema (1)
- hierarchy (1)
- hippocampal neuronal cell line (1)
- histone acetylation (1)
- histone deacetylase (1)
- histone deacetylase 5 (1)
- host-targeting antivirals (1)
- human biology and medicine (1)
- human papilloma virus (1)
- human renal proximal tubular epithelial cells (1)
- humanized mouse (1)
- humans (1)
- humoral factors (1)
- hybrid (1)
- hydrocephalus (1)
- hydroxyapatite crystals (1)
- hyperbaric oxygen treatment (1)
- hyperlipidemia (1)
- hypothalamus (1)
- hypoxia-induced cell death (1)
- imitation (1)
- immune (1)
- immune reconstitution (1)
- immunohistochemistry (1)
- in-cabin exposure (1)
- inducible gene expression (1)
- infectivity (1)
- inflammasome (1)
- influenza (1)
- influenza vaccine (1)
- information decomposition (1)
- inhaler (1)
- innate lymphoid cells (1)
- insulin resistance (1)
- integration (1)
- integrin (1)
- integrins (1)
- interferon (1)
- interferon gamma (1)
- interleukin-1 (1)
- interleukin-18 (1)
- interleukin-1β (1)
- interleukin-23 receptor (1)
- interneurons (1)
- interstitial brachytherapy (1)
- intervertebral disc degeneration (1)
- intestinal graft-versushost disease (1)
- intracellular trafficking (1)
- intraperitoneal therapy (1)
- intraventricular chemotherapy (1)
- invasion (1)
- ionomycin (1)
- irradiation (1)
- ischemic type biliary lesions (1)
- isocaloric ketogenic diet (1)
- isovaleric acidaemia (1)
- kavalactones (1)
- keratinocytes (1)
- kinase inhibitor (1)
- knockout mice (1)
- knowledge discovery (1)
- laceration (1)
- lapatinib (1)
- late lumen loss (1)
- layer 1 (1)
- leptomeningeal metastases (1)
- levetiracetam (1)
- lipoxygenase (1)
- liver cirrhosis (1)
- liver fibrosis (1)
- liver transplantation (1)
- long-acting muscarinic antagonist (1)
- long-term follow-up (1)
- long-term infusion (1)
- longevity (1)
- lung cancer (1)
- lung remodeling (1)
- lung transplantation (1)
- lymphocyte (1)
- lymphoma (1)
- mTOR (1)
- mTOR inhibitor (1)
- mTORC1 (1)
- machine-learning (1)
- macula (1)
- magnetoencephalography (1)
- maintenance (1)
- malignancy (1)
- marginal bone loss (1)
- markovianity (1)
- massively parallel multigrid solvers (1)
- maternal care (1)
- mathematical modeling (1)
- measure development/validation (1)
- mechanobactericidal surfaces (1)
- medical illustration (1)
- medical school (1)
- medication reconciliation (1)
- memebrane (1)
- mentoring (1)
- metabolic cancer therapy (1)
- metamorphosis (1)
- metastatic (1)
- methotrexate (1)
- methyltransferases (1)
- miR-122 (1)
- miR-21 (1)
- microdosing (1)
- microsaccades (1)
- microsatellite instability (1)
- microwave breast imaging (1)
- migrants (1)
- migration (1)
- mitochondrial disease (1)
- mobile air quality study (1)
- moisturing cream (1)
- molecular identification (1)
- molecular mechanisms (1)
- momilactone A (1)
- momilactone B (1)
- monkey (1)
- mouse (1)
- multidrug resistance (1)
- multimorbidity (1)
- multinucleated giant cells (1)
- multiple chronic conditions (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multisite cooperation (1)
- myocyte enhancer factor 2 (1)
- nanostructures (1)
- natural killer T cells (1)
- natural killer cell (1)
- neocortical circuits (1)
- neoepitopes (1)
- neonatal intensive care unit (1)
- neonate (1)
- neural network (1)
- neural oscillations (1)
- neuraminidase inhibitor (1)
- neuro-ophthalmological examination (1)
- neuroblastoma (1)
- neurocognition (1)
- neurocritical care (1)
- neurogenesis (1)
- neurological emergencies (1)
- neuromodulation (1)
- neurophysiology (1)
- neuropilin-1 (1)
- nitric oxide (1)
- nitro-fatty acids (1)
- non-ST-segment elevation acute coronary syndrome (1)
- nonalcoholic fatty liver disease (1)
- nonalcoholic steatohepatitis (1)
- nonviral gene delivery (1)
- novel psychoactive substance (1)
- nursery school students (1)
- nursery schools (1)
- nursery students (1)
- nurses (1)
- obese (1)
- object tracking (1)
- omega-3 fatty acids (1)
- oncogene (1)
- one health (1)
- open-source (1)
- oral kallikrein inhibitor (1)
- orthopic liver transplantation (1)
- oscillations (1)
- oseltamivir (1)
- ostium (1)
- outcome (1)
- outcomes (1)
- ovarian cancer (1)
- oxygen (1)
- p21-activated kinase 2 (1)
- p38 (1)
- p97 (1)
- pCREB (1)
- palbociclib (1)
- palmitoylation (1)
- papilloma (1)
- parameter estimation (1)
- parsley (1)
- particle size distribution (1)
- particulate matter (1)
- patency (1)
- patient study (1)
- patients (1)
- pentose phosphate pathway (1)
- pericytes (1)
- peripheral artery disease (1)
- peripheral vascular diseases (1)
- peritoneal carcinomatosis (1)
- persistent atrial fibrillation (1)
- persisting pain (1)
- personalized oncology (1)
- pertuzumab (1)
- pessary (1)
- pharmacology (1)
- phase III (1)
- phase-1 (1)
- phenolics (1)
- phenylephrine (1)
- phosphate (1)
- photoaging (1)
- physical activity (1)
- physical activity promotion (1)
- physical activity recommendations (1)
- pictilisib (1)
- pig (1)
- pivalate (1)
- pivoloyl (1)
- plasminogen (1)
- platform-switched (1)
- polarization (1)
- poly(I:C) (1)
- poly(lactic-co-glycolic acid) (PLGA) (1)
- polydipsia (1)
- polylactic acid (PLA) (1)
- polymerase chain reaction (1)
- polypharmacy (1)
- polyphenols (1)
- polytrauma (1)
- polyuria (1)
- popliteal artery (1)
- porcine (1)
- post-transplantation lymphoproliferative disease (1)
- posttranslational modification (1)
- pre-emptive allogeneic hematopoietic stem cell transplantation (1)
- preclinical semesters (1)
- preconditioning (1)
- pressure (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- preterm (1)
- preterm birth (1)
- pretreatment (1)
- prevalence of hysterectomy (1)
- prevent smoking (1)
- primary cilium (1)
- primary healthcare (1)
- primary mouse proximal tubular cells (1)
- progesterone (1)
- programmed cell death ligand 1 (1)
- programmed cell death protein 1 (1)
- proliferation (1)
- prophylaxis (1)
- propofol anesthesia (1)
- prospective memory (1)
- prostaglandin E2 (1)
- prostate cancer (1)
- protein kinase D (1)
- protein kinases (1)
- proteomics (1)
- pruritus (1)
- psoriatic arthritis (1)
- psychological questionnaires (1)
- psychometric properties (1)
- publication (1)
- pulmonary arterial hypertension (1)
- pulmonary inflammation (1)
- pulmonary vein isolation (1)
- qPCR (1)
- qRT-PCR (1)
- qualitative research (1)
- quality control (1)
- radical scavenging chemicals (1)
- radiofrequency (1)
- radiotherapy (1)
- radiotherapy resistance (1)
- rare diseases (1)
- rat (1)
- real-world evidence (1)
- realistic geometries (1)
- redox signalling (1)
- redox-linked proton translocation (1)
- redundancy (1)
- redundant information (1)
- reference values (1)
- regulatory T cell (1)
- relapsing–remitting (1)
- reliability (1)
- remote ischemic preconditioning (1)
- renal cell cancer (1)
- renal cell carcinoma (1)
- renal failure (1)
- renal ischemia reperfusion injury (1)
- research consortium (1)
- resilience (1)
- respiratory complex I (1)
- restenosis (1)
- restrictive atrial communication (1)
- retina (1)
- retinoic acid-related orphan receptor gamma t (1)
- rhodocetin-αβ (1)
- rhythm (1)
- ribociclib (1)
- rice husk (1)
- risk assessment (1)
- rural health program (1)
- saliva (1)
- school-based prevention (1)
- scientometrics (1)
- scientometry (1)
- screening routine (1)
- secretion (1)
- selection (1)
- selective attention (1)
- selective mutism, (1)
- semen (1)
- sensitization (1)
- sensory neurons (1)
- sequential ALK-inhibitor therapy (1)
- shedding (1)
- shell ginger (1)
- shortage of family doctors (1)
- siRNA (1)
- signaling (1)
- silence interfering RNA (1)
- sirtuin1 (1)
- sirtuins (1)
- skeletal muscle (1)
- skin (1)
- smoking (1)
- smoking cessation (1)
- solvent displacement (1)
- somatostatin interneurons (1)
- sonidegib (1)
- spatial (1)
- sphinganine 1-phosphate (1)
- sphingosine kinase 1 (1)
- spinster homology protein 2 (Spns2) (1)
- spirochetes (1)
- squamous cell carcinoma (1)
- standard value (1)
- stem cell niche (1)
- stem cells (1)
- stenosis (1)
- stenosis quantification (1)
- sterol regulatory element binding protein-2 (1)
- stroke (1)
- structural biology and molecular biophysics (1)
- subcutaneous immunotherapy (1)
- sublingual immunotherapy (1)
- subventricular zone (1)
- superficial femoral artery (1)
- syncope (1)
- synergy (1)
- tear (1)
- temozolomide (1)
- temperature (1)
- temsirolimus (1)
- testicular cancer (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- thymus (1)
- titanium (1)
- titanium particles (1)
- tobacco (1)
- tobacco cessation (1)
- tomography (1)
- top-down processing (1)
- topical agent (1)
- total events (1)
- total flavonoids (1)
- total phenols (1)
- toxicity (1)
- tracking (1)
- traffic emissions (1)
- transcatheter aortic valve replacement (1)
- transcranial magnetic stimulation (1)
- transcriptome analysis (1)
- transfemoral (1)
- transgelin (1)
- transient elastography (1)
- transiente Elastographie (1)
- transketolase-like protein 1 (1)
- translational cancer research (1)
- transposition (1)
- trastuzumab (1)
- trauma (1)
- trehalose (1)
- tubular regeneration (1)
- tumor metabolism (1)
- tumor-infiltrating lymphocytes (1)
- type B (1)
- ubiquitin (1)
- unique information (1)
- upper gastrointestinal cancer (1)
- vaccination rates (1)
- vaccine (1)
- vaccine acceptance (1)
- vaccine trial (1)
- validity (1)
- vascular calcification (1)
- vascular endothelial growth factor receptor 2 (1)
- vascular smooth muscle cells (1)
- vasculogenic mimicry (1)
- vasoconstriction (1)
- vasodilation (1)
- vasopressin (1)
- ventilation modes (1)
- ventral striatum (1)
- ventriculoperitoneal shunt (1)
- vesicular glutamate transporter 2 (1)
- vessel-associated mural cells (1)
- videos (1)
- viral dynamics (1)
- virus (1)
- virus-like particles (1)
- vision (1)
- vismodegib (1)
- vismodegib (GDC-0449) (1)
- visual cortex (1)
- visuo-spatial attention (1)
- vitamin D (1)
- vitamin D receptor (1)
- wear (1)
- white-matter (1)
- wild animals (1)
- willingness to participate (1)
- within-host viral modelling (1)
- working memory (1)
- wound healing (1)
- yield optimization (1)
- ß-D-glucan (1)
- α-mannosidosis (1)
Institute
- Medizin (472)
- Präsidium (14)
- Sonderforschungsbereiche / Forschungskollegs (14)
- Exzellenzcluster Makromolekulare Komplexe (9)
- Biowissenschaften (8)
- Sportwissenschaften (8)
- Exzellenzcluster Herz-Lungen-System (7)
- Georg-Speyer-Haus (6)
- Pharmazie (6)
- Psychologie (6)
Objective: Classifications of posture deviations are only possible compared with standard values. However, standard values have been published for healthy male adults but not for female adults.
Design: Observational study.
Setting: Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University Frankfurt/Main.
Participants: 106 healthy female volunteers (21–30 years old; 25.1±2.7 years) were included. Their body weight ranged from 46 to 106 kg (60.3±7.9 kg), the heights from 1.53 to 1.82 m (1.69±0.06 m) and the body mass index from 16.9 kg/m² to 37.6 kg/m² (21.1±2.6 kg/m²).
Outcome measures: A three-dimensional back scan was performed to measure the upper back posture in habitual standing. The tolerance ranges and CI were calculated. Group differences were tested by the Wilcoxon Mann-Whitney U test.
Results: In normal posture, the spinal column was marginally twisted to the left, and the vertebrae were marginally rotated to the right. The kyphosis angle is larger than the lumbar angle. Consequently, a more kyphotic posture is observed in the sagittal plane. The habitual posture is slightly scoliotic with a rotational component (scapular depression right, right scapula marginally more dorsally, high state of pelvic right, iliac right further rotated anteriorly).
Conclusions: Healthy young women have an almost ideally balanced posture with minimal ventral body inclination and a marginal scoliotic deviation. Compared with young males, women show only marginal differences in the upper body posture. These values allow a comparison to other studies, both for control and patient data, and may serve as guideline in both clinical practice and scientific studies.
Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE).
Method: A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017.
Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (n = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or 50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%.
Significance: In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.
Our ability to select relevant information from the environment is limited by the resolution of attention – i.e., the minimum size of the region that can be selected. Neural mechanisms that underlie this limit and its development are not yet understood. Functional magnetic resonance imaging (fMRI) was performed during an object tracking task in 7- and 11-year-old children, and in young adults. Object tracking activated canonical fronto-parietal attention systems and motion-sensitive area MT in children as young as 7 years. Object tracking performance improved with age, together with stronger recruitment of parietal attention areas and a shift from low-level to higher-level visual areas. Increasing the required resolution of spatial attention – which was implemented by varying the distance between target and distractors in the object tracking task – led to activation increases in fronto-insular cortex, medial frontal cortex including anterior cingulate cortex (ACC) and supplementary motor area, superior colliculi, and thalamus. This core circuitry for attentional precision was recruited by all age groups, but ACC showed an age-related activation reduction. Our results suggest that age-related improvements in selective visual attention and in the resolution of attention are characterized by an increased use of more functionally specialized brain regions during the course of development.
Parkinson’s disease (PD) is characterized by distinct motor and non-motor symptoms. Sleep disorders are the most frequent and challenging non-motor symptoms in PD patients, and there is growing evidence that they are a consequence of disruptions within the circadian system. PD is characterized by a progressive degeneration of the dorsal vagal nucleus and midbrain dopaminergic neurons together with an imbalance of many other neurotransmitters. Mutations in α-synuclein (SNCA), a protein modulating SNARE complex-dependent neurotransmission, trigger dominantly inherited PD variants and sporadic cases of PD. The A53T SNCA missense mutation is associated with an autosomal dominant early-onset familial PD. To test whether this missense mutation affects the circadian system, we analyzed the spontaneous locomotor behavior of non-transgenic wildtype mice and transgenic mice overexpressing mutant human A53T α-synuclein (A53T). The mice were subjected to entrained- and free-running conditions as well as to experimental jet lag. Furthermore, the vesicular glutamate transporter 2 (VGLUT2) in the suprachiasmatic nucleus (SCN) was analyzed by immunohistochemistry. Free-running circadian rhythm and, thus, circadian rhythm generation, were not affected in A53T mice. A53T mice entrained to the light–dark cycle, however, with an advanced phase angle of 2.65 ± 0.5 h before lights off. Moreover, re-entrainment after experimental jet lag was impaired in A53T mice. Finally, VGLUT2 immunoreaction was reduced in the SCN of A53T mice. These data suggest an impaired light entrainment of the circadian system in A53T mice.
Chronic kidney disease and diabetes mellitus are associated with extensive media calcification, which leads to increased cardiovascular morbidity and mortality. Here, we investigated the role of autophagy in the pathogenesis of uremic vascular media calcification. DBA/2 mice were fed with high-phosphate diet (HPD) in order to cause vascular calcification. DBA/2 mice on standard chow diet were used as control. In parallel, autophagy and its response to rapamycin, 3-methyladenine (3-MA), and bafilomycin were studied in an in vitro model using mouse vascular smooth muscle cells (MOVAS). DBA/2 mice on HPD developed severe vascular media calcification, which is mirrored in vitro by culturing MOVAS under calcifying conditions. Both, in vitro and in vivo, autophagy significantly increased in MOVAS under calcifying conditions and in aortas of HPD mice, respectively. Histologically, autophagy was located to the aortic Tunica media, but also vascular endothelial cells, and was found to continuously increase during HPD treatment. 3-MA as well as bafilomycin blocked autophagy in MOVAS and increased calcification. Vice versa, rapamycin treatment further increased autophagy and resulted in a significant decrease of vascular calcification in vitro and in vivo. Rapamycin reduced Runx2 transcription levels in aortas and MOVAS to control levels, whereas it increased α-smooth muscle actin and Sm22α transcription in MOVAS to control levels. Furthermore, rapamycin-treated HPD mice survived significantly longer compared to HPD controls. These findings indicate that autophagy is an endogenous response of vascular smooth muscle cells (VSMC) to protect from calcification in uremia. Induction of autophagy by rapamycin protects cells and mice from uremic media calcification possibly by inhibiting osteogenic transdifferentiation of VSMC.
Rapid immune reconstitution (IR) following stem cell transplantation (SCT) is essential for a favorable outcome. The optimization of graft composition should not only enable a sufficient IR but also improve graft vs. leukemia/tumor effects, overcome infectious complications and, finally, improve patient survival. Especially in haploidentical SCT, the optimization of graft composition is controversial. Therefore, we analyzed the influence of graft manipulation on IR in 40 patients with acute leukemia in remission. We examined the cell recovery post haploidentical SCT in patients receiving a CD34+-selected or CD3/CD19-depleted graft, considering the applied conditioning regimen. We used joint model analysis for overall survival (OS) and analyzed the dynamics of age-adjusted leukocytes; lymphocytes; monocytes; CD3+, CD3+CD4+, and CD3+CD8+ T cells; natural killer (NK) cells; and B cells over the course of time after SCT. Lymphocytes, NK cells, and B cells expanded more rapidly after SCT with CD34+-selected grafts (P = 0.036, P = 0.002, and P < 0.001, respectively). Contrarily, CD3+CD4+ helper T cells recovered delayer in the CD34 selected group (P = 0.026). Furthermore, reduced intensity conditioning facilitated faster immune recovery of lymphocytes and T cells and their subsets (P < 0.001). However, the immune recovery for NK cells and B cells was comparable for patients who received reduced-intensity or full preparative regimens. Dynamics of all cell types had a significant influence on OS, which did not differ between patients receiving CD34+-selected and those receiving CD3/CD19-depleted grafts. In conclusion, cell reconstitution dynamics showed complex diversity with regard to the graft manufacturing procedure and conditioning regimen.
An aerosol foam formulation of a once-daily, fixed-dose combination of a synthetic vitamin D3 analog/synthetic corticosteroid (calcipotriol [Cal] 50 µg/g and betamethasone dipropionate [BD] 0.5 mg/g) has recently been introduced for the topical treatment of plaque psoriasis in adults. Data from several sources – randomized controlled trials, case reports (as highlighted in this review), and real-world evidence (RWE) – underscore the considerable and rapid clinical response, effectiveness, and favorable safety and tolerability of Cal/BD aerosol foam in mild-to-moderate psoriatic patients previously treated with class 3 or 4 topical corticosteroids, in patients unsatisfied with ongoing phototherapy in combination with topical therapy and in patients with moderate-to-severe psoriasis. In addition, our case series, considered together with other RWE, highlights that Cal/BD aerosol foam is more effective and with greater levels of patient preference and acceptability than comparator preparations. Thus, Cal/BD aerosol foam offers several treatment advantages, including relief of itch, and is an appropriate first-line topical therapy for consideration in patients with psoriasis of any severity.
Damaged mitochondria are selectively eliminated by mitophagy. Parkin and PINK1, gene products mutated in familial Parkinson’s disease, play essential roles in mitophagy through ubiquitination of mitochondria. Cargo ubiquitination by E3 ubiquitin ligase Parkin is important to trigger selective autophagy. Although autophagy receptors recruit LC3-labeled autophagic membranes onto damaged mitochondria, how other essential autophagy units such as ATG9A-integrated vesicles are recruited remains unclear. Here, using mammalian cultured cells, we demonstrate that RABGEF1, the upstream factor of the endosomal Rab GTPase cascade, is recruited to damaged mitochondria via ubiquitin binding downstream of Parkin. RABGEF1 directs the downstream Rab proteins, RAB5 and RAB7A, to damaged mitochondria, whose associations are further regulated by mitochondrial Rab-GAPs. Furthermore, depletion of RAB7A inhibited ATG9A vesicle assembly and subsequent encapsulation of the mitochondria by autophagic membranes. These results strongly suggest that endosomal Rab cycles on damaged mitochondria are a crucial regulator of mitophagy through assembling ATG9A vesicles.
Background: There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for germline BRCA1 and BRCA2 (gBRCA) mutations. Here, we explored the association of age at TNBC diagnosis with the prevalence of pathogenic gBRCA mutations in this patient group.
Methods: The study comprised 802 women (median age 40 years, range 19–76) with oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 negative breast cancers, who had no relatives with breast or ovarian cancer. All women were tested for pathogenic gBRCA mutations. Logistic regression analysis was used to explore the association between age at TNBC diagnosis and the presence of a pathogenic gBRCA mutation.
Results: A total of 127 women with TNBC (15.8%) were gBRCA mutation carriers (BRCA1: n = 118, 14.7%; BRCA2: n = 9, 1.1%). The mutation prevalence was 32.9% in the age group 20–29 years compared to 6.9% in the age group 60–69 years. Logistic regression analysis revealed a significant increase of mutation frequency with decreasing age at diagnosis (odds ratio 1.87 per 10 year decrease, 95%CI 1.50–2.32, p < 0.001). gBRCA mutation risk was predicted to be > 10% for women diagnosed below approximately 50 years.
Conclusions: Based on the general understanding that a heterozygous mutation probability of 10% or greater justifies gBRCA mutation screening, women with TNBC diagnosed before the age of 50 years and no familial history of breast and ovarian cancer should be tested for gBRCA mutations. In Germany, this would concern approximately 880 women with newly diagnosed TNBC per year, of whom approximately 150 are expected to be identified as carriers of a pathogenic gBRCA mutation.
Background: The city of Wrocław in Poland represents one of Central Europeans oldest capitals of science with numerous Nobel laureates. Due to a long history of political suppressions with Nazi Germany and Communism from 1933 until 1989, its scientific community was suppressed for more than half a century.
Methods: The present study assessed scientific activities in the field of social and neighbouring sciences using density equalizing mapping. On the basis of the NewQIS (New Quality and Quantity Indices in Science) platform and the Social Sciences Citation Index (SSCI) of the Web of Science database, a total of 1787 articles originating from Wrocław were identified between 1966 and 2017.
Results: In total, 549 research collaborations of Wrocław with 96 different countries were present (30.7%). Among the 107 research areas the highest activity was found for the field of Business and Economics with n = 272 articles (average citation rate (AVR) of 12.54), followed by Psychology (n = 252 articles, AVR = 9.06), Psychiatry (n = 205 articles, AVR = 4.74) and Public, Environmental and Occupational Health (n = 145 articles, AVR = 7.96). The highest AVR was found for Operations Research (25.36 with n = 87 articles). Density equalizing mapping procedures revealed a global pattern of social sciences research collaborations with scientists from Germany, the UK and the US as the primary cooperating partner of Wrocław. The different countries had major differences in the area of research collaborations.
Conclusions: This is the first study that depicts the global network of Wrocław scientific activities in the field of social sciences. The exorbitant increase in research activity from 2006 onwards can lead to the assumption that Wrocław social sciences encounter a fruitful future.
Determining the cell fate and the distribution of mesenchymal stromal/stem cells (MSCs) after transplantation are essential parts of characterizing the mechanisms of action and biosafety profile of stem cell therapy. Many recent studies have shown that MSCs migrate into injured tissues, but are only detectable at extremely low frequencies. We investigated the cell fate of MSCs after transplantation in an acute kidney injury (AKI) mouse model using in vivo bioluminescence imaging (BLI) and subsequent verification of cell migration using quantitative real-time polymerase chain reaction (qRT-PCR). The AKI was induced by a single injection of cisplatin (8 or 12 mg/kg). One day later, adipose-derived mesenchymal stromal/stem cells isolated from luciferase transgenic mice (Luc+-mASCs, 5 × 105) were intravenously transplanted. Migration kinetics of the cells was monitored using BLI on day 1, 3, and 6, and finally via quantitative real-time PCR at the endpoint on day 6. Using BLI, infused Luc+-mASCs could only be detected in the lungs, but not in the kidneys. In contrast, PCR endpoint analysis revealed that Luc-specific mRNA could be detected in injured renal tissue; compared to the control group, the induction was 2.2-fold higher for the 8 mg/kg cisplatin group (p < 0.05), respectively 6.1-fold for the 12 mg/kg cisplatin group (p < 0.001). In conclusion, our study demonstrated that Luc-based real-time PCR rather than BLI is likely to be a better tool for cell tracking after transplantation in models such as cisplatin-induced AKI.
GD2-directed immunotherapies improve survival of high-risk neuroblastoma (NB) patients (pts). Treatment with chimeric anti-GD2 antibodies (Ab), such as ch14.18, can induce development of human anti-chimeric Ab (HACA). Here, we report HACA effects on ch14.18/CHO pharmacokinetics, pharmacodynamics and pain intensity in pts treated by long-term infusion (LTI) of ch14.18/CHO combined with IL-2. 124 pts received up to 5 cycles of ch14.18/CHO 10 days (d) infusion (10 mg/m2/d; d8–18) combined with s.c. IL-2 (6 × 106 IU/m2/d; d1–5, d8–12). HACA, treatment toxicity, ch14.18/CHO levels, Ab-dependent cellular- (ADCC) and complement-dependent cytotoxicity (CDC) were assessed using respective validated assays. HACA-negative pts showed a steadily decreased pain in cycle 1 (74% pts without morphine by d5 of LTI) with further decrease in subsequent cycles. Ch14.18/CHO peak concentrations of 11.26 ± 0.50 µg/mL found in cycle 1 were further elevated in subsequent cycles and resulted in robust GD2-specific CDC and ADCC. Development of HACA (21% of pts) resulted in strong reduction of ch14.18/CHO levels, abrogated CDC and ADCC. Surprisingly, no difference in pain toxicity between HACA-positive and -negative pts was found. In conclusion, ch14.18/CHO LTI combined with IL-2 results in strong activation of Ab effector functions. Importantly, HACA response abrogated CDC but did not affect pain intensity indicating CDC-independent pain induction.
Introduction: Hip fracture surgery is associated with high in-hospital and 30-day mortality rates and serious adverse patient outcomes. Evidence from randomised controlled trials regarding effectiveness of spinal versus general anaesthesia on patient-centred outcomes after hip fracture surgery is sparse.
Methods and analysis: The iHOPE study is a pragmatic national, multicentre, randomised controlled, open-label clinical trial with a two-arm parallel group design. In total, 1032 patients with hip fracture (>65 years) will be randomised in an intended 1:1 allocation ratio to receive spinal anaesthesia (n=516) or general anaesthesia (n=516). Outcome assessment will occur in a blinded manner after hospital discharge and inhospital. The primary endpoint will be assessed by telephone interview and comprises the time to the first occurring event of the binary composite outcome of all-cause mortality or new-onset serious cardiac and pulmonary complications within 30 postoperative days. In-hospital secondary endpoints, assessed via in-person interviews and medical record review, include mortality, perioperative adverse events, delirium, satisfaction, walking independently, length of hospital stay and discharge destination. Telephone interviews will be performed for long-term endpoints (all-cause mortality, independence in walking, chronic pain, ability to return home cognitive function and overall health and disability) at postoperative day 30±3, 180±45 and 365±60.
Ethics and dissemination: iHOPE has been approved by the leading Ethics Committee of the Medical Faculty of the RWTH Aachen University on 14 March 2018 (EK 022/18). Approval from all other involved local Ethical Committees was subsequently requested and obtained. Study started in April 2018 with a total recruitment period of 24 months. iHOPE will be disseminated via presentations at national and international scientific meetings or conferences and publication in peer-reviewed international scientific journals.
Trial registration number: DRKS00013644; Pre-results
Isolated complex I deficiency is a common biochemical phenotype observed in pediatric mitochondrial disease and often arises as a consequence of pathogenic variants affecting one of the ∼65 genes encoding the complex I structural subunits or assembly factors. Such genetic heterogeneity means that application of next-generation sequencing technologies to undiagnosed cohorts has been a catalyst for genetic diagnosis and gene-disease associations. We describe the clinical and molecular genetic investigations of four unrelated children who presented with neuroradiological findings and/or elevated lactate levels, highly suggestive of an underlying mitochondrial diagnosis. Next-generation sequencing identified bi-allelic variants in NDUFA6, encoding a 15 kDa LYR-motif-containing complex I subunit that forms part of the Q-module. Functional investigations using subjects’ fibroblast cell lines demonstrated complex I assembly defects, which were characterized in detail by mass-spectrometry-based complexome profiling. This confirmed a marked reduction in incorporated NDUFA6 and a concomitant reduction in other Q-module subunits, including NDUFAB1, NDUFA7, and NDUFA12. Lentiviral transduction of subjects’ fibroblasts showed normalization of complex I. These data also support supercomplex formation, whereby the ∼830 kDa complex I intermediate (consisting of the P- and Q-modules) is in complex with assembled complex III and IV holoenzymes despite lacking the N-module. Interestingly, RNA-sequencing data provided evidence that the consensus RefSeq accession number does not correspond to the predominant transcript in clinically relevant tissues, prompting revision of the NDUFA6 RefSeq transcript and highlighting not only the importance of thorough variant interpretation but also the assessment of appropriate transcripts for analysis.
Aims: The ILUVIEN Registry Safety Study is an ongoing, multicentre, open-label, observational study collecting real-world data on the safety and effectiveness of the 0.2 µg/day fluocinolone acetonide (FAc) implant in patients treated according to the European label requirements.
Methods: Patients included in this analysis were treated for the licensed indication of chronic diabetic macular oedema (cDMO; that is, DMO that persists or recurs despite treatment). Data presented in the current analysis were collected from patient records up to 6 March 2017. Visual acuity (VA) data, including mean change in VA over time and at last observation, intraocular pressure (IOP) over the course of the study, IOP events, use of IOP-lowering therapy and cup:disc ratio were analysed. Information on additional DMO treatments post-FAc implant was also captured.
Results: Five hundred and sixty-three patients (593 eyes) were enrolled on the study. Mean IOP for the overall population remained within the normal range throughout follow-up and 76.7% of patients did not require IOP-lowering therapy following treatment with the FAc implant. Sixty-nine per cent of eyes did not require additional DMO treatments. Mean VA in the overall population increased from 51.9 letters at baseline to 55.6 letters at month 12, with a significant increase of 2.9 letters at last observation. Patients with short-term cDMO experienced greater VA gains than those with long-term cDMO.
Conclusions: The results of this analysis are comparable with those of other studies, including the Fluocinolone Acetate for Macular Edema study. The study reinforces the good safety and effectiveness profile of FAc, and demonstrates the benefit of early FAc treatment.
Oral anticoagulant-associated intracerebral hemorrhage (OAC-ICH) accounts for nearly 20% of all ICH. The number of patients with an indication for oral anticoagulant therapy (OAT) increases with increasing age. OAT became less complicate with the introduction of non-vitamin K oral anticoagulants (NOAC) OAT because of easier handling, favorable risk-benefit profile, reduced rates of ICH compared to vitamin K antagonists and no need for routine coagulation testing. Consequently, despite a better safety profile of NOAC the number of patients with OAC-ICH will increase. The mortality and complication rates of OAC-ICH are high and therefore they are the most feared complication of OAT. Immediate normalization of coagulation is the main goal and therefore knowledge of pharmacodynamics and coagulation status is essential. Laboratory measurements of anticoagulant activity in NOAC patients is challenging as specific tests are not widely available. More accessible tests such as the prothrombin time and activated partial thromboplastin time have important limitations. In dabigatran-associated ICH 5 g Idarucizumab should be administered. In rivaroxaban and apixaban-associated ICHs administration of andexanet alpha should be considered. Prothrombin complex concentrate may be considered if andexanet alpha is not available or in case of an ICH associated with edoxaban.
The authors review the current status of percutaneous left atrial appendage (LAA) occlusion therapy in patients with atrial fibrillation with the goal to prevent ischemic stroke and systemic embolism and to reduce oral anticoagulation associated bleeding. While we cover the historical and also surgical background, and all tested devices, the main focus rests on the single currently U.S. Food and Drug Administration (FDA) approved LAA occluder, the WATCHMAN device, and its approval process. The authors also give a critical appraisal beyond the review of mere facts, trying to put the current data into perspective.
Background: Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these devices has not been undertaken or shown to be superior to a sham procedure.
Methods: We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated.
Discussion: This trial could help to identify the most effective and safest endoscopic device, thus determining the new standard procedure for endoscopic bariatric treatment.
Trial registration: 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).
Different response of Ptch mutant and Ptch wildtype Rhabdomyosarcoma toward SMO and PI3K inhibitors
(2018)
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma with poor prognosis. RMS frequently show Hedgehog (HH) pathway activity, which is predominantly seen in the embryonal subtype (ERMS). They also show activation of Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling. Here we compared the therapeutic effectiveness and the impact on HH target gene expression of Smoothened (SMO) antagonists with those of the PI3K inhibitor pictilisib in ERMS with and without mutations in the HH receptor Patched1 (PTCH). Our data demonstrate that growth of ERMS showing canonical Hh signaling activity due to Ptch germline mutations is efficiently reduced by SMO antagonists. This goes along with strong downregulation of the Hh target Gli1. Likewise Ptch mutant tumors are highly responsive toward the PI3K inhibitor pictilisib, which involves modulation of AKT and caspase activity. Pictilisib also modulates Hh target gene expression, which, however, is rather not correlated with its antitumoral effects. In contrast, sporadic ERMS, which usually express HH target genes without having PTCH mutation, apparently lack canonical HH signaling activity. Thus, stimulation by Sonic HE (SHH) or SAG (Smoothened agonist) or inhibition by SMO antagonists do not modulate HH target gene expression. In addition, SMO antagonists do not provoke efficient anticancer effects and rather exert off-target effects. In contrast, pictilisib and other PI3K/AKT/mTOR inhibitors potently inhibit cellular growth. They also efficiently inhibit HH target gene expression. However, of whether this is correlated with their antitumoral effects it is not clear. Together, these data suggest that PI3K inhibitors are a good and reliable therapeutic option for all ERMS, whereas SMO inhibitors might only be beneficial for ERMS driven by PTCH mutations.
Danger signals in trauma
(2018)
This review summarizes a short list of currently discussed trauma-induced danger-associated molecular patterns (DAMP). Due to the bivalent character and often pleiotropic effects of a DAMP, it is difficult to describe its “friend or foe” role in post-traumatic inflammation and regeneration, both systemically as well locally in tissues. DAMP can be used as biomarkers to indicate or monitor disease or injury severity, but also may serve as clinically applicable parameters for better indication and timing of surgery. Due to the inflammatory processes at the local tissue level or the systemic level, the precise role of DAMP is not always clear to define. While in vitro and experimental studies allow for the detection of these biomarkers at the different levels of an organism—cellular, tissue, circulation—this is not always easily transferable to the human setting. Increased knowledge exploring the dual role of DAMP after trauma, and concentrating on their nuclear functions, transcriptional targets, release mechanisms, cellular sources, multiple functions, their interactions and potential therapeutic targeting is warranted.
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver events in lung adenocarcinoma. Accurate and reliable detection of these gene fusions is crucial to select the appropriate targeted therapy for each patient. We compared the targeted next-generation-sequencing Oncomine Focus Assay (OFA; Thermo Fisher Scientific) with conventional ALK FISH and anti-Alk immunohistochemistry in a cohort of 52 lung adenocarcinomas (10 ALK rearranged, 18 non-ALK rearranged, and 24 untested cases). We found a sensitivity and specificity of 100% for detection of ALK rearrangements using the OFA panel. In addition, targeted next generation sequencing allowed us to analyze a set of 23 driver genes in a single assay. Besides EML4-ALK (11/52 cases), we detected EZR-ROS1 (1/52 cases), KIF5B-RET (1/52 cases) and MET-MET (4/52 cases) fusions. All EML4-ALK, EZR-ROS1 and KIF5B-RET fusions were confirmed by multiplexed targeted next generation sequencing assay (Oncomine Solid Tumor Fusion Transcript Kit, Thermo Fisher Scientific). All cases with EML4-ALK rearrangement were confirmed by Alk immunohistochemistry and all but one by ALK FISH. In our experience, targeted next-generation sequencing is a reliable and timesaving tool for multiplexed detection of targetable rearrangements. Therefore, targeted next-generation sequencing represents an efficient alternative to time-consuming single target assays currently used in molecular pathology.
Objective. Traumatic injury or severe surgery leads to a profound immune response with a diminished functionality of monocytes and subsequently their IL-1β release. IL-1β plays an important role in host immunity and protection against infections. Its biological activation via IL-1β-precursor processing requires the transcription of inflammasome components and their activation. Deregulated activity of NOD-like receptor inflammasomes (NLR) like NLRP3 that leads to the maturation of IL-1β has been described in various diseases. While the role of other inflammasomes has been studied in monocytes, nothing is known about NLRP3 inflammasome after a traumatic injury. Here, the role of the NLRP3 inflammasome in impaired monocyte functionality after a traumatic injury was analyzed.
Measurements and Main Results. Ex vivo-in vitro stimulation of isolated CD14+ monocytes with lipopolysaccharide (LPS) showed a significantly higher IL-1β secretion in healthy volunteers (HV) compared to trauma patients (TP) after admission. Reduced IL-1β secretion was paralleled by significantly lowered gene expression of NLRP3 in monocytes from TP compared to those of HV. Transfection of monocytes with NLRP3-encoding plasmid recovered the functionality of monocytes from TP regarding the IL-1β secretion.
Conclusions. This study demonstrates that CD14+ monocytes from TP are significantly diminished in their function and that the presence of NLRP3 components is necessary in recovering the ability of monocytes to produce active IL-1β. This recovery of the NLRP3 inflammasome in monocytes may imply a new target for treatment and therapy of immune suppression after severe injury.
New technologies and therapies designed to facilitate development of personalized treatments are rapidly emerging in the field of biomedicine. Strikingly, the goal of personalized medicine refined the concept of therapy by developing cell-based therapies, the so-called “living drugs”. Breakthrough advancements were achieved in this regard in the fields of gene therapy, cell therapy, tissue-engineered products and advanced therapeutic techniques. The Advanced Therapies in Healthcare symposium, organized by the Clinical Research Center Department of Sidra Medicine, in Doha, Qatar (October 2017), brought together world-renowned experts from the fields of oncology, hematology, immunology, inflammation, autoimmune disorders, and stem cells to offer a comprehensive picture of the status of worldwide advanced therapies in both pre-clinical and clinical development, providing insights to the research phase, clinical data and regulatory aspects of these therapies. Highlights of the meeting are provided in this meeting report.
Background: Histological evidence suggests that autism spectrum disorder (ASD) is accompanied by a reduced integrity of the grey-white matter boundary. This has also recently been confirmed by a structural neuroimaging study in vivo reporting significantly reduced grey-white matter tissue contrast (GWC) in adult individuals (18–42 years of age) with ASD relative to typically developing (TD) controls. However, it remains unknown whether the neuroanatomical differences in ASD at the grey-white matter boundary are stable across development or are age-dependent.
Methods: Here, we examined differences in the neurodevelopmental trajectories of GWC in a cross-sectional sample of 77 male ASD individuals and 76 typically developing (TD) controls across childhood and early adulthood (from 7 to 25 years).
Results: Using nested model comparisons, we first established that the developmental trajectory of GWC is complex in many regions across the cortex and includes linear and non-linear effects of age. Second, while ASD individuals have significantly reduced GWC overall, these differences are age-dependent and are most prominent during childhood (< 15 years).
Conclusions: Taken together, our findings suggest that differences in GWC in ASD are unlikely to reflect atypical grey matter cytoarchitecture alone, but may also represent other aspects of the cortical architecture such as age-dependent variability in myelin integrity.
Background: The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC).
Methods: First, miRNA expression profiles were determined in exosomes derived from the plasma of 15 TNBC patients before neoadjuvant therapy using a quantitative TaqMan real-time PCR-based microRNA array card containing 384 different miRNAs. Forty-five miRNAs associated with different clinical parameters were then selected and mounted on microRNA array cards that served for the quantification of exosomal miRNAs in 435 BC patients before therapy and 20 healthy women. Confocal microscopy, Western blot, and ELISA were used for exosome characterization.
Results: Quantification of 45 exosomal miRNAs showed that compared with healthy women, 10 miRNAs in the entire cohort of BC patients, 13 in the subgroup of 211 HER2-positive BC, and 17 in the subgroup of 224 TNBC were significantly deregulated. Plasma levels of 18 exosomal miRNAs differed between HER2-positive and TNBC subtypes, and 9 miRNAs of them also differed from healthy women. Exosomal miRNAs were significantly associated with the clinicopathological and risk factors. In uni- and multivariate models, miR-155 (p = 0.002, p = 0.003, respectively) and miR-301 (p = 0.002, p = 0.001, respectively) best predicted pathological complete response (pCR).
Conclusion: Our findings show a network of deregulated exosomal miRNAs with specific expression patterns in exosomes of HER2-positive and TNBC patients that are also associated with clinicopathological parameters and pCR within each BC subtype.
We examined alterations in E/I-balance in schizophrenia (ScZ) through measurements of resting-state gamma-band activity in participants meeting clinical high-risk (CHR) criteria (n = 88), 21 first episode (FEP) patients and 34 chronic ScZ-patients. Furthermore, MRS-data were obtained in CHR-participants and matched controls. Magnetoencephalographic (MEG) resting-state activity was examined at source level and MEG-data were correlated with neuropsychological scores and clinical symptoms. CHR-participants were characterized by increased 64–90 Hz power. In contrast, FEP- and ScZ-patients showed aberrant spectral power at both low- and high gamma-band frequencies. MRS-data showed a shift in E/I-balance toward increased excitation in CHR-participants, which correlated with increased occipital gamma-band power. Finally, neuropsychological deficits and clinical symptoms in FEP and ScZ-patients were correlated with reduced gamma band-activity, while elevated psychotic symptoms in the CHR group showed the opposite relationship. The current study suggests that resting-state gamma-band power and altered Glx/GABA ratio indicate changes in E/I-balance parameters across illness stages in ScZ.
Background: This study assessed the impact of medical students’ emotion recognition ability and extraversion on their empathic communication, as perceived by simulated patients in a training context.
Methods: This study used a crossed-effect data structure and examined 245 students in their fourth year of medical school. The students’ personality traits were assessed based on a self-assessment questionnaire of the short form of the Big Five Inventory; their emotion recognition ability was measured using a performance test (Diagnostic Analysis of Nonverbal Accuracy-2, Adult Facial Expressions). Simulated patients evaluated the medical students’ empathic communication.
Results: Students with a combination of high emotion recognition ability and extraversion received more positive ratings from simulated patients than their fellow students with a combination of emotion recognition ability and low extraversion. The main effects of emotion recognition or extraversion were not sufficient to yield similar effects. There were no other effects related to the remaining Big Five variables.
Conclusions: The results support the hypothesis that to build rapport with patients, medical staff need to combine emotional capabilities with a dispositional interest in interpersonal encounters.
Most studies in the life sciences and other disciplines involve generating and analyzing numerical data of some type as the foundation for scientific findings. Working with numerical data involves multiple challenges. These include reproducible data acquisition, appropriate data storage, computationally correct data analysis, appropriate reporting and presentation of the results, and suitable data interpretation.
Finding and correcting mistakes when analyzing and interpreting data can be frustrating and time-consuming. Presenting or publishing incorrect results is embarrassing but not uncommon. Particular sources of errors are inappropriate use of statistical methods and incorrect interpretation of data by software. To detect mistakes as early as possible, one should frequently check intermediate and final results for plausibility. Clearly documenting how quantities and results were obtained facilitates correcting mistakes. Properly understanding data is indispensable for reaching well-founded conclusions from experimental results. Units are needed to make sense of numbers, and uncertainty should be estimated to know how meaningful results are. Descriptive statistics and significance testing are useful tools for interpreting numerical results if applied correctly. However, blindly trusting in computed numbers can also be misleading, so it is worth thinking about how data should be summarized quantitatively to properly answer the question at hand. Finally, a suitable form of presentation is needed so that the data can properly support the interpretation and findings. By additionally sharing the relevant data, others can access, understand, and ultimately make use of the results.
These quick tips are intended to provide guidelines for correctly interpreting, efficiently analyzing, and presenting numerical data in a useful way.
Perception of irony has been observed to be impaired in adults with autism spectrum disorder. In typically developed adults, the mismatch of verbal and nonverbal emotional cues can be perceived as an expression of irony even in the absence of any further contextual information. In this study, we evaluate to what extent high functioning autists perceive this incongruence as expressing irony. Our results show that incongruent verbal and nonverbal signals create an impression of irony significantly less often in participants with high-functioning autism than in typically developed control subjects. The extent of overall autistic symptomatology as measured with the autism-spectrum questionnaire (AQ), however, does not correlate with the reduced tendency to attribute incongruent stimuli as expressing irony. Therefore, the attenuation in irony attribution might rather be related to specific subdomains of autistic traits, such as a reduced tendency to interpret communicative signals in terms of complex intentional mental states. The observed differences in irony attribution support the assumption that a less pronounced tendency to engage in higher order mentalization processes might underlie the impairment of pragmatic language understanding in high functioning autism.
Fibroblasts were isolated from skin biopsies from two patients with bipolar I disorder. One patient was a 26 year old female carrying a risk haplotype in the DGKH (diacylglycerol kinase eta) gene and the other was a non-carrier 27 year old male. Patient fibroblasts were reprogrammed into human induced pluripotent stem cells (hiPSCs) by using a Sendai virus vector. DGKH-risk haplotype and non-risk haplotype hiPSCs showed expression of pluripotency markers and were able to differentiate into cells of the three germ layers. These cell models are useful to investigate the role of risk gene variants in bipolar disorder.
Radiographic outcomes following lateral alveolar ridge augmentation using autogenous tooth roots
(2018)
Background: To assess and compare the radiographic outcomes following lateral alveolar ridge augmentation using autogenous tooth roots (TR) and autogenous bone (AB) blocks.
Methods: In a total of 30 patients, lateral ridge augmentation was conducted in parallel groups using either (1) healthy autogenous tooth roots (e.g., retained wisdom or impacted teeth) (n = 15) or (2) cortical autogenous bone blocks harvested from the retromolar area. Cone-beam computed tomographic (CBCT) scans taken at 26 weeks of submerged healing were analyzed for the basal graft integration (i.e., contact between the graft and the host bone in %) (BI26) and the cross-sectional grafted area (mm2) (SA26).
Results: Both groups revealed a comparable clinical width of the alveolar ridge at baseline (CWb). Mean BI26 and SA26 values amounted to 69.26 ± 26.01% (median 72.44) and 22.07 ± 12.98 mm2 (median 18.83) in the TR group and 79.67 ± 15.66% (median 78.85) and 12.42 ± 10.11 mm2 (median 11.36) in the AB group, respectively. Between-group differences in mean SA26 values were statistically significant (p = 0.031). Linear regression analysis failed to reveal any significant correlations between BI26 and CWb/SA26 values in either group.
Conclusions: TR grafts may be associated with improved SA26 values following lateral alveolar ridge augmentation.
Trial registration: DRKS00009586. Registered 10 February 2016.
Background: In Germany, patients suffering from life-limiting conditions are eligible for specialized outpatient palliative care (SOPC). Evaluation of the quality of this service lacks currently integration of patient-relevant outcomes. There is also no scientific consensus how to prove quality of care in the special context of SOPC adequately. Existing quality reports are primarily based on descriptive structural data which do not allow for estimation of process quality or result quality. The ELSAH study ("Evaluation of Specialized Outpatient Palliative Care in the German state of Hesse") aims to choose - or, if necessary, to adopt - to evaluate and to implement a suit of measures to assess, evaluate and monitor the quality of specialized, home-based palliative care.
Methods: All 22 SOPC teams providing their services in the state of Hesse, Germany, participate in the ELSAH study. The study is divided in two phases: a preparation phase and a main study phase. Based on the findings of the preparation phase we have chosen a preliminary set of instruments including the Integrated Palliative Outcome Scale, Views on Care, Zarit Burden Interview, Phase of Illness, Goal Attainment Scaling, Eastern Cooperative Oncology Group Performance Status, Consumer Quality Indices Palliative Care and Sense of Security in Care. During the main study phase, we will use a mixed-methods approach to evaluate the instruments’ psychometric properties (reliability, validity, feasibility and practicability), to identify barriers, facilitators and limitations of their routine use and to explore how their use affects the care within the SOPC setting.
Discussion: At the end of this study, an outcome- and patient-centered, validated measurement approach should be provided, adapted for standardized evaluations in SOPC across patient groups, palliative care services and regions nationwide. The standardized application of instruments should allow for making valid statements and comparisons of health care quality in SOPC based on process- and outcome-evaluation rather than relying on structural data only. Moreover, the instruments might directly influence the care of patients in palliative situations.
Trial registration: German Clinical Trials Register (DRKS-ID: DRKS00012421).
Background: Many gene variants modulate the individual perception of pain and possibly also its persistence. The limited selection of single functional variants is increasingly being replaced by analyses of the full coding and regulatory sequences of pain-relevant genes accessible by means of next generation sequencing (NGS).
Methods: An NGS panel was created for a set of 77 human genes selected following different lines of evidence supporting their role in persisting pain. To address the role of these candidate genes, we established a sequencing assay based on a custom AmpliSeqTM panel to assess the exomic sequences in 72 subjects of Caucasian ethnicity. To identify the systems biology of the genes, the biological functions associated with these genes were assessed by means of a computational over-representation analysis.
Results: Sequencing generated a median of 2.85 ⋅ 106 reads per run with a mean depth close to 200 reads, mean read length of 205 called bases and an average chip loading of 71%. A total of 3,185 genetic variants were called. A computational functional genomics analysis indicated that the proposed NGS gene panel covers biological processes identified previously as characterizing the functional genomics of persisting pain.
Conclusion: Results of the NGS assay suggested that the produced nucleotide sequences are comparable to those earned with the classical Sanger sequencing technique. The assay is applicable for small to large-scale experimental setups to target the accessing of information about any nucleotide within the addressed genes in a study cohort.
Background: Ataxia telangiectasia (A-T) is a devastating multi-system disorder characterized by progressive cerebellar ataxia, growth retardation, immunodeficiency, chronic pulmonary disease and chromosomal instability. Cutaneous granulomas are a known phenomenon in A-T but extra-dermal manifestation of granulomas at bone and synovia has not been reported so far. The clinical presentation, immunological findings, the long-term course and treatment options of eight patients with severe granulomas will be reported.
Methods: From our cohort of 44 classical A-T patients, eight patients aged 2–11 years (18.2%) presented with granulomas. Immunological features of patients with and without granulomas were compared. Five patients suffered from cutaneous manifestation, in two patients we detected a bone and in one a joint involvement. Patients with significant extra-dermal involvement as well as one patient with massive skin manifestation were treated with TNF inhibitors. The patient with granulomas at his finger joint and elbow was treated with hematopoietic stem cell transplantation (HSCT).
Results: Interestingly, seven of eight patients with granulomas were total IgA deficient, but there were no differences in IgG and IgM levels. All lymphocytes subsets were equally distributed except patients with granuloma had significantly lower naïve CD8 cells. In patients without treatment, four of eight showed a slow but significant enlargement of the granuloma. Treatment success with TNF inhibitors was variable. In one patient, treatment with TNF inhibitors led to a total remission for 3 years up to now. In two patients, treatment with TNF inhibitors led to a partial regression of granulomas. Treatment interruptions caused deterioration again.
Conclusions: Granulomas in A-T progress slowly over years and can lead to significant morbidity.Treatment with TNF inhibitors was safe and in part successful in our patients. Interestingly HSCT leads to complete remission, and indicates that aberrant immune function is responsible for granulomas in A-T patients.
At a glance commentary:
Scientific knowledge on the subject: Little is known about the clinical presentation, course and treatment of granulomas in ataxia telangiectasia (A-T). In addition, this is the first report of extra-dermal manifestation of granulomas at bone and synovia in patients with A-T.
What This Study Adds to the Field: Granulomas in A-T progress slowly over years and can lead to significant morbidity. Treatment with TNF inhibitors was safe and in part successful in our patients.
Background and purpose: The astroglial protein GFAP is a blood biomarker indicative of intracerebral hemorrhage in patients with acute stroke. Due to its brain specificity and the necessity of brain damage for its detectability in blood, we hypothesized that GFAP could be an interesting marker in cases with primary cerebral cause of death, e.g., traumatic brain injury.
Methods: All corpses scheduled for an autopsy in the Frankfurt Department of Forensic medicine within a 15-month period were included in the study. Cases with a known history of brain disease in the 3 months before death were excluded. During autopsy, blood was collected and GFAP serum levels were determined using a commercially available ELISA. The autopsy protocols were reviewed for the presence of a primary cerebral or a primary non-cerebral cause of death. Agony time was also determined.
Results: A total of 129 autopsy cases were included. GFAP concentrations did not differ between cerebral (median 0.96 μg/l, IQR 5.03) and non-cerebral causes of death (1.21 μg/l, 3.58). GFAP levels were found to be unaffected by hemolysis or post-mortem interval. GFAP levels were found to be increased in cases with prolonged agony times (median 1.76 μg/l [IQR 4.70]) compared to short (0.58 μg/l [0.58]; p<0.001) and ultra-short agony times (0.21 μg/l [0.12]; p = 0.002).
Conclusion: Post-mortem GFAP serum concentrations correlate with agony time and might therefore be useful for the evaluation of the severity of brain damage in prolonged death. Elevated GFAP serum levels do not indicate a primary cerebral cause of death.
Background: Transient elastography (TE) has been validated as an effective noninvasive tool for the assessment of liver fibrosis. The XL probe is a new probe that was initially designed for use in patients with obesity. A meta-analysis was performed to assess the feasibility and efficacy of TE using the XL probe.
Methods: In September 2016, we systematically searched the PubMed and Science Direct search engines. The feasibility of TE was evaluated based on the failure rate and the results of the unreliable liver stiffness measurement (LSM). The efficacy of TE was measured using sensitivity, specificity, and summary receiver-operating characteristic as measures/indices assessed in different stages of fibrosis. Heterogeneity was measured using the chi-squared test and the Q-statistic. We used the 95% confidence interval (95% CI) as an effect measure.
Results: We included 8 studies in the meta-analysis. When the XL was compared to the M probe, the former showed a lower risk of failure rate [relative risk (RR) 0.24, 95% CI 0.14–0.38]. In patients with a body mass index ≥30 kg/m2, the XL probe showed a statistically significantly lower risk of failure rate (RR 0.16, 95% CI 0.08–0.32) but no significant improvement (RR 0.76, 95% CI 0.50–1.16) in the unreliable LSM result. In patients showing liver fibrosis stage ≥F2, the XL probe showed a sensitivity of 0.56 (95% CI 0.39–0.72), specificity of 0.71 (95% CI 0.61–0.79), and an area under the curve (AUC) of 0.71. The results observed in patients with liver fibrosis stage F4 were more promising with a sensitivity of 0.84 (95% CI 0.76–0.90), specificity of 0.78 (95% CI 0.70–0.84), and an AUC of 0.88.
Conclusion: TE using the XL probe demonstrates significant diagnostic utility in patients with liver fibrosis and is likely to be more reliable than the M probe in patients with obesity. Large prospective multicenter studies are, however, necessary to establish the new cut-off values to be used for the XL probe in patients with obesity.
Based on increasing evidence suggesting that MS pathology involves alterations in bioactive lipid metabolism, the present analysis was aimed at generating a complex serum lipid-biomarker. Using unsupervised machine-learning, implemented as emergent self-organizing maps of neuronal networks, swarm intelligence and Minimum Curvilinear Embedding, a cluster structure was found in the input data space comprising serum concentrations of d = 43 different lipid-markers of various classes. The structure coincided largely with the clinical diagnosis, indicating that the data provide a basis for the creation of a biomarker (classifier). This was subsequently assessed using supervised machine-learning, implemented as random forests and computed ABC analysis-based feature selection. Bayesian statistics-based biomarker creation was used to map the diagnostic classes of either MS patients (n = 102) or healthy subjects (n = 301). Eight lipid-markers passed the feature selection and comprised GluCerC16, LPA20:4, HETE15S, LacCerC24:1, C16Sphinganine, biopterin and the endocannabinoids PEA and OEA. A complex classifier or biomarker was developed that predicted MS at a sensitivity, specificity and accuracy of approximately 95% in training and test data sets, respectively. The present successful application of serum lipid marker concentrations to MS data is encouraging for further efforts to establish an MS biomarker based on serum lipidomics.
A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets
(2018)
NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCRB6C14R strain. Ly5.1C14R NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46C14R in 293T cells showed that NKp46 protein trafficking to the cell surface was compromised. Although Ly5.1C14R mice had normal number of NK cells, they showed an increased number of early maturation stage NK cells. CD49a+ILC1s were also increased but these cells lacked the expression of TRAIL. ILC3s that expressed NKp46 were not detectable and were not apparent when examined by T-bet expression. Thus, the C14R mutation reveals that NKp46 is important for NK cell and ILC differentiation, maturation and function.
Objective: The correlation of depleted blood through midline shift in acute subdural hematoma remains the most reliable clinical predictor to date. On the other hand, patient’s ABO blood type has a profound impact on coagulation and hemostasis. We conducted this study to evaluate the role of patient’s blood type in terms of incidence, clinical course and outcome after acute subdural hematoma bleeding.
Methods: 100 patients with acute subdural hematoma treated between 2010 and 2015 at the author’s institution were included. Baseline characteristics and clinical findings including Glasgow coma scale, Glasgow outcome scale, hematoma volume, rebleeding, midline shift, postoperative seizures and the presence of anticoagulation were analyzed for their association with ABO blood type.
Results: Patient’s with blood type O were found to have a lower midline shift (p<0.01) and significantly less seizures (OR: 0.43; p<0.05) compared to non-O patients. Furthermore, patients with blood type A had the a significantly higher midline shift (p<0.05) and a significantly increased risk for postoperative seizures (OR: 4.01; p<0.001). There was no difference in ABO blood type distribution between acute subdural hematoma patients and the average population.
Conclusion: The ABO blood type has significant influence on acute subdural hematoma sequelae. Patient’s with blood type O benefit in their clinical course after acute subdural hematoma whereas blood type A patients are at highest risk for increased midline shift and postoperative seizures. Further studies elucidating the biological mechanisms of blood type depended hemostaseology and its role in acute subdural hematoma are required for the development of an appropriate intervention.
Locomotion circuits developed in simple animals, and circuit motifs further evolved in higher animals. To understand locomotion circuit motifs, they must be characterized in many models. The nematode Caenorhabditis elegans possesses one of the best-studied circuits for undulatory movement. Yet, for 1/6th of the cholinergic motor neurons (MNs), the AS MNs, functional information is unavailable. Ventral nerve cord (VNC) MNs coordinate undulations, in small circuits of complementary neurons innervating opposing muscles. AS MNs differ, as they innervate muscles and other MNs asymmetrically, without complementary partners. We characterized AS MNs by optogenetic, behavioral and imaging analyses. They generate asymmetric muscle activation, enabling navigation, and contribute to coordination of dorso-ventral undulation as well as anterio-posterior bending wave propagation. AS MN activity correlated with forward and backward locomotion, and they functionally connect to premotor interneurons (PINs) for both locomotion regimes. Electrical feedback from AS MNs via gap junctions may affect only backward PINs.
Viscum album L. extracts (VE) are applied as complementary cancer therapeutics for more than one century. Extracts contain several compounds like mistletoe lectins (ML) 1-3 and viscotoxins, but also several minor ingredients. Since ML-1 has been described as one of the main active components harboring antitumor activity, purified native or recombinant ML-1 has been also used in clinical trials in the last years. The present study examined and compared the immunoboosting effects of three ML-1 containing drugs (the extract ISCADOR Qu, the recombinant ML-1 Aviscumine, and purified native ML-1) in the context of the T-cell mediated killing of glioma cells. Additionally we examined the possible underlying T-cell stimulating mechanisms. Using cocultures of immune and glioma cells, a PCR-based microarray, quantitative RT-PCR, and an antibody-based array to measure cytokines in blood serum, immunosupporting effects were determined. A highly aggressive, orthotopic, immunocompetent syngeneic mouse glioma model was used to determine the survival of mice treated with ISCADOR Qu alone or in combination with tumor irradiation and temozolomide (TMZ). Treatment of glioblastoma (GBM) cells with ISCADOR Qu that contains a high ML concentration, but also viscotoxins and other compounds, as well as with Aviscumine or native ML-1, enhanced the expansion of cancer cell-specific T-cells as well as T-cell-mediated tumor cell lysis, but to a different degree. In GBM cells all three ML-1-containing preparations modulated the expression of immune response associated genes. In vivo, subcutaneous ISCADOR Qu injections at increasing concentration induced cytokine release in immunocompetent VM/Dk-mice. Finally, ISCADOR Qu, if applied in combination with tumor irradiation and TMZ, further prolonged the survival of glioma mice. Our findings indicate that ML-1 containing drugs enhance anti-GBM immune responses and work in synergy with radiochemotherapy. Therefore, adjuvant mistletoe therapy should be considered as an auspicious treatment option for glioma patients.
Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B‐cell malignancies. Notwithstanding, CAR T‐cell manufacturing requires complex procedures impeding the broad supply chain. Here, we provide evidence that human CD19‐CAR T cells can be generated directly in vivo using the lentiviral vector CD8‐LV specifically targeting human CD8+ cells. Administration into mice xenografted with Raji lymphoma cells and human peripheral blood mononuclear cells led to CAR expression solely in CD8+ T cells and efficacious elimination of CD19+ B cells. Further, upon injection of CD8‐LV into mice transplanted with human CD34+ cells, induction of CAR T cells and CD19+ B‐cell depletion was observed in 7 out of 10 treated animals. Notably, three mice showed elevated levels of human cytokines in plasma. Tissue‐invading CAR T cells and complete elimination of the B‐lymphocyte‐rich zones in spleen were indicative of a cytokine release syndrome. Our data demonstrate the feasibility of in vivo reprogramming of human CD8+ CAR T cells active against CD19+ cells, yet with similar adverse effects currently notorious in the clinical practice.
Aberrant activation of hedgehog (Hh) signaling has been observed in a wide variety of tumors and accounts for more than 25% of human cancer deaths. Inhibitors targeting the Hh signal transducer Smoothened (SMO) are widely used and display a good initial efficacy in patients suffering from basal cell carcinoma (BCC); however, a large number of patients relapse. Though SMO mutations may explain acquired therapy resistance, a growing body of evidence suggests that the non-canonical, SMO-independent activation of the Hh pathway in BCC patients can also account for this adverse effect. In this review, we highlight the importance of glioma-associated oncogene (GLI) transcription factors (the main downstream effectors of the canonical and the non-canonical Hh cascade) and their putative role in the regulation of multiple oncogenic signaling pathways. Moreover, we discuss the contribution of the Hh signaling to malignant transformation and propose GLIs as central hubs in tumor signaling networks and thus attractive molecular targets in anti-cancer therapies.
The regulation of temporo-spatial compartmentalization of protein synthesis is of crucial importance for a variety of physiologic cellular functions. Here, we demonstrate that the cell membrane-anchored disintegrin metalloproteinase ADAM15, upregulated in a variety of aggressively growing tumor cells, in the hyperproliferative synovial membrane of inflamed joints as well as in osteoarthritic chondrocytes, transiently binds to poly(A) binding protein 1 (PABP) in cells undergoing adhesion. The cytoplasmic domain of ADAM15 was shown to selectively interact with the proline-rich linker of PABP. Immunostainings of adhesion-triggered cells demonstrate an ADAM15-dependent recruitment of PABP to cell membrane foci coinciding with ongoing mRNA translation as visualized by the detection of puromycin-terminated polypeptides. Moreover, the increase in cell membrane-associated neosynthesis of puromycylated proteins upon induction of cell adhesion was proven linked to ADAM15 expression in HeLa and ADAM15-transfected chondrocytic cells. Thus, down regulation of ADAM15 by siRNA and/or the use of a cell line transfected with a mutant ADAM15-construct lacking the cytoplasmic tail resulted in a considerable reduction in the amount of cell membrane-associated puromycylated proteins formed during induced cell adhesion.
These results provide first direct evidence for a regulatory role of ADAM15 on mRNA translation at the cell membrane that transiently emerges in response to triggering cell adhesion and might have potential implications under pathologic conditions of matrix remodeling associated with ADAM15 upregulation.
Background: Recently, public and political interest has focused on people living with rare diseases and their health concerns. Due to the large number of different types of rare diseases and the sizable number of patients, taking action to improve the life of those affected is gaining importance. In 2013, the federal government of Germany adopted a national action plan for rare diseases, including the call to establish a central information portal on rare diseases (Zentrales Informationsportal über seltene Erkrankungen, ZIPSE).
Objective: The objective of this study, therefore, was to conduct scientific research on how such a portal must be designed to meet the needs of patients, their families, and medical professionals, and to provide high-quality information for information seekers.
Methods: We chose a 3-step procedure to develop a needs-based prototype of a central information portal. In the first step, we determined the information needs of patients with rare diseases, their relatives, and health care professionals by means of qualitative interviews and their content-analytical evaluation. On the basis of this, we developed the basic structure of the portal. In the second step, we identified quality criteria for websites on rare diseases to ensure that the information linked with ZIPSE meets the quality demands. Therefore, we gathered existing criteria catalogs and discussed them in an expert workshop. In the third step, we implemented and tested the developed prototypical information portal.
Results: A portal page was configured and made accessible on the Web. The structure of ZIPSE was based on the findings from 108 qualitative interviews with patients, their relatives, and health care professionals, through which numerous information needs were identified. We placed particularly important areas of information, such as symptoms, therapy, research, and advisory services, on the start page. Moreover, we defined 13 quality criteria, referring to factors such as author information, creation date, and privacy, enabling links with high-quality information. Moreover, 19 users tested all the developed routines based on usability and comprehensibility. Subsequently, we improved the visual presentation of search results and other important search functions.
Conclusions: The implemented information portal, ZIPSE, provides high-quality information on rare diseases from a central point of access. By integrating the targeted groups as well as different experts on medical information during the construction, the website can assure an improved search for information for users. ZIPSE can also serve as a model for other Web-based information systems in the field of rare diseases.
Registered Report Identifier: RR1-10.2196/7425.
Objective: To conduct subset analyses of SPIRIT-P2 (Standard Protocol Items: Recommendations for Interventional Trials, NCT02349295) to investigate the efficacy and safety of ixekizumab versus placebo in three subgroups of patients with active psoriatic arthritis (PsA) according to the concomitant conventional synthetic disease-modifying antirheumatic drug (cDMARD) received: any background cDMARDs (including methotrexate), background methotrexate only
Methods: Patients were randomised to receive placebo, ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W). Efficacy and safety were assessed when patients were subdivided according to cDMARD use at baseline. Efficacy was evaluated versus placebo at week 24 by the American College of Rheumatology criteria (ACR20/50), achievement of minimal disease activity (MDA) state, DiseaseActivityIndex for PsA (DAPSA), 28-joint DiseaseActivityScore using C reactive protein (DAS28-CRP), HealthAssessmentQuestionnaire-Disability Index and the 36-item Short-Form health survey physical functioning domain.
Results: Regardless of background cDMARD status, ACR20, ACR50 and MDA response rates were significantly higher than placebo with IXEQ4W or IXEQ2W treatment. Similarly, significant improvements were observed relative to placebo for DAS28-CRP and DAPSA across subgroups. Physical function also significantly improved relative to placebo with IXEQ4W treatment regardless of background cDMARD status and with IXEQ2W alone. Percentages of reported treatment emergent adverse events (AEs), serious AEs (including serious infections) and discontinuations due to AEs in each subgroup were comparable to the overall SPIRIT-P2 population.
Conclusion: Ixekizumab was efficacious in patients with active PsA and previous tumour necrosis factor inhibitor (TNFi)inadequate response or TNFi intolerance treated with ixekizumab alone or when added to cDMARDswith subgroup safety profiles that were consistent with that observed in the overall SPIRIT-P2 population.
Cardiovascular disease remains a leading cause of morbidity and mortality globally. Changing natural history of the disease due to improved care of acute conditions and ageing population necessitates new strategies to tackle conditions which have more chronic and indolent course. These include an increased deployment of safe screening methods, life-long surveillance, and monitoring of both disease activity and tailored-treatment, by way of increasingly personalized medical care. Cardiovascular magnetic resonance (CMR) is a non-invasive, ionising radiation-free method, which can support a significant number of clinically relevant measurements and offers new opportunities to advance the state of art of diagnosis, prognosis and treatment. The objective of the SCMR Clinical Trial Taskforce was to summarizes the evidence to emphasize where currently CMR-guided clinical care can indeed translate into meaningful use and efficient deployment of resources results in meaningful and efficient use. The objective of the present initiative was to provide an appraisal of evidence on analytical validation, including the accuracy and precision, and clinical qualification of parameters in disease context, clarifying the strengths and weaknesses of the state of art, as well as the gaps in the current evidence This paper is complementary to the existing position papers on standardized acquisition and post-processing ensuring robustness and transferability for widespread use. Themed imaging-endpoint guidance on trial design to support drug-discovery or change in clinical practice (part II), will be presented in a follow-up paper in due course. As CMR continues to undergo rapid development, regular updates of the present recommendations are foreseen.
Background: Conversion from calcineurin inhibitor (CNI) therapy to a mammalian target of rapamycin (mTOR) inhibitor following kidney transplantation may help to preserve graft function. Data are sparse, however, concerning the impact of conversion on posttransplant diabetes mellitus (PTDM) or the progression of pre-existing diabetes.
Methods: PTDM and other diabetes-related parameters were assessed post hoc in two large open-label multicenter trials. Kidney transplant recipients were randomized (i) at month 4.5 to switch to everolimus or remain on a standard cyclosporine (CsA)-based regimen (ZEUS, n = 300), or (ii) at month 3 to switch to everolimus, remain on standard CNI therapy or convert to everolimus with reduced-exposure CsA (HERAKLES, n = 497).
Results: There were no significant differences in the incidence of PTDM between treatment groups (log rank p = 0.97 [ZEUS], p = 0.90 [HERAKLES]). The mean change in random blood glucose from randomization to month 12 was also similar between treatment groups in both trials for patients with or without PTDM, and with or without pre-existing diabetes. The change in eGFR from randomization to month 12 showed a benefit for everolimus versus comparator groups in all subpopulations, but only reached significance in larger subgroups (no PTDM or no pre-existing diabetes).
Conclusions: Within the restrictions of this post hoc analysis, including non-standardized diagnostic criteria and limited glycemia laboratory parameters, these data do not indicate any difference in the incidence or severity of PTDM with early conversion from a CsA-based regimen to everolimus, or in the progression of pre-existing diabetes.
Trial registration: clinicaltrials.gov, NCT00154310 (registered September 2005) and NCT00514514 (registered August 2007); EudraCT (2006-007021-32 and 2004-004346-40).